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BACKGROUND: Estrogen metabolites, sex-steroid hormones, and breast density are associated 
with breast carcinogenesis.   
OBJECTIVE: Complete a systematic study of the contribution of two biological measures 
(breast density and hormone metabolism) to an endocrine-based model of breast cancer risk. 
METHODS: The study groups included breast cancer-free participants (N=282) in the Study of 
Osteoporotic Fractures (SOF), and participants in the Mammogram and Masses Study (MAMS), 
inclusive of 176 cases (55 pre-menopausal, 121 post-menopausal) and 380 controls (124 pre-
menopausal, 256 postmenopausal).  Sex-steroid hormones, percent breast density, serum 
concentrations of 2-hydroxyestrone (2-OH) and 16 alpha-hydroxyestrone (16α-OH), and breast 
cancer risk factors were evaluated to determine associations. 
RESULTS: In SOF, 16α-OH was positively associated with body mass index (BMI) (r=0.162); 
however, this association was not significant in multivariate analyses that controlled for the 
serum sex-steroid hormone concentrations (total estradiol, total testosterone, SHBG).  Women 
who reported a surgical menopause were significantly more likely to have higher levels of 16α-
OH (OR=(tertile 3 vs tertile 1) 7.37, 95% Confidence Interval (CI) 2.20-24.70), but there was no 
type of menopause difference with respect to 2-OH tertile.  In all MAMS control subjects 
(N=380), breast density correlated weakly with log-transformed serum concentrations of 16α-OH 
(Pearson correlation coefficient (ρ) = 0.10, p-value < 0.1).  Stratification according to 
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menopausal status substantially reduced or eliminated associations between breast density and 
the estrogen metabolite concentrations.  Logistic regression analyses showed a 3-4 fold increased 
risk of breast cancer among pre-menopausal women in the highest tertile of breast density 
compared with those in the lowest tertile of density, even with adjustment for the estrogen 
metabolites.  A statistically non-significant 1.5-fold increased risk of breast cancer in high vs. 
low tertile of density was observed among post-menopausal women taking hormone therapy 
(HT) after adjusting for estrogen metabolites, BMI, and age.  Breast density did not appear to 
substantially increase breast cancer risk among post-menopausal women not taking HT.   
CONCLUSION: In SOF, results did not show consistent associations between risk factors and 
estrogen metabolites except for a positive association between BMI and 16α-OH and surgical 
menopause and 16α-OH.  With respect to MAMS, menopausal status may influence substrate 
estrogen hormone levels primarily, and, estrogen hormone levels may influence breast density 
secondarily, through pathways not involving the estrogen metabolites.  The breast density-breast 
cancer association remains significant even with adjustment for the estrogen metabolites, at least 
in pre-menopausal women, suggesting that breast density may relate to breast cancer risk through 
pathways not involving estrogen metabolism. 
PUBLIC HEALTH SIGNIFICANCE: Understanding factors that affect breast density and 
their underlying mechanism is an important public health issue.  Such an understanding will help 
us improve breast cancer screening and may help us identify women who are at an increased risk 
of breast cancer and for whom prevention strategies may be useful.      
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 1. INTRODUCTION 
 
 
In the following review of literature, a brief description of the epidemiology of breast cancer, 
mammographic density, and estrogen metabolism will be followed by a review of the potential 
relationship among these factors. 
Among women, breast cancer is the most common cancer and is second only to lung 
cancer in the number of deaths per year.  In 2005, approximately 211,240 new cases of invasive 
breast cancer and 58,490 in situ cases will be diagnosed in the United States and 40,410 women 
will die from breast cancer(1).  The five-year relative survival rate is 98% if the cancer is limited 
to the breast at diagnosis, 81% if the regional lymph nodes are involved, and 26% if the cancer 
has spread to a distant site(1).   
Thus, breast cancer represents a major burden to women, and methods to impact risk 
identification and modification are paramount.  An improved understanding of risk factors has 
led to recommendations for risk reduction, as well as raised additional questions as to the 
underlying mechanisms of this disease.   
 
1.1. Age 
The greatest risk of breast cancer occurs with increasing age, with incidence doubling every 10 
years until menopause(67, 85).  When evaluating the distribution of breast cancer diagnosis by 
age, there is a steady incline (Figure 1).  While the slopes are different between pre- and 
postmenopausal women, it is evident that the rise is steady without evidence of a plateau.  This 
increasing risk may be indicative of the lifetime accumulation of exposures to those risk factors, 
known and unknown, as well as genetic events throughout the lifetime.   
1 
 Figure 1-1:  ACS Facts and Figures 2004 
1.2. Geographic Variation 
While age is a significant risk factor, age alone cannot explain the great variation noted among 
different countries.  The influence of environment and lifestyle factors is probable in explaining 
the difference among countries.  In studies evaluating migrants, the incidence of breast cancer 
assumes that of the host country within one or two generations(85).  Currently, there is 
approximately a five fold difference in age-adjusted incidence and mortality between Far Eastern 
and Western countries.   
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1.3. Race 
In figure 2, it is apparent that while Caucasian women have a higher incidence, the mortality in 
Black women remains higher.  Potential reasons include disparities in access to care which may 
in turn lead to prognostic features such as later stage at diagnosis and increased mortality.  
Additionally, the incidence of comorbid conditions may impact the mortality rate.  However, 
different biologic features may be the etiology in explaining the differences among race.  When 
looking at estrogen receptor (ER) and progesterone receptor (PR) status across Caucasians, 
Blacks, and Hispanics, it is evident that Caucasians are more likely to present with ER/PR 
positive tumors which is a good prognostic feature (figure 3)(46).  This supports the idea that 
although access to care is a real issue, biologic differences exist and warrant further 
investigation. 
 
 Figure 1-2: SEER Data Incidence & Mortality Rates by Race 1975-2002 
3 
       
 
 
Steroid receptor status by age in years and ethnic group. A) Estrogen receptor (ER). B) 
Progesterone receptor (PgR). Numbers in parentheses = total number of patients 
 
Figure 1-3: ER/PR Status Across Race, Elledge, JNCI 1994 
 
 
1.4. Family History/Genetics 
The notion that breast cancer “runs in families” is not a new one.  However, the etiology is 
questionable.  Certainly these women generally share the same environmental exposures and 
lifestyle factors which may alone contribute to the increased risk.  If a woman has a first degree 
relative with bilateral breast cancer or ovarian cancer, or a first degree relative diagnosed with 
breast cancer under the age of 40, her risk is three times that of the population(85).  However, the 
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role of genetics has also been questioned.  While there are probably many unidentified breast 
cancer genes, to date we are aware of two: BRCA1 and BRCA2.  These genes are located on 
chromosomes 17 and 13 respectively and account for 5%-10% of all breast cancer cases.  
Mutations in these two independent, highly penetrant autosomal dominant loci are thought to 
account for the majority of inherited cancer cases(27, 92).  In 100 families with at least one case 
of breast and ovarian cancer evaluated at a high-risk breast evaluation clinic, deleterious 
germline mutations in BRCA1 and BRCA2 were found in 55%(82).  Methods to measure 
BRCA1 and BRCA2 as well as methods to reduce risk continue to be studied(20). 
 
1.5. Benign Breast Disease 
In clinical follow-up studies evidence has indicated that there is a relationship between the 
presence of histologically proven benign breast disease and breast cancer risk, and the level of 
risk varies according to the histologic category of benign breast disease. Particularly, 
proliferative lesions without atypia are associated with a 1.5- to 2-fold increase in risk, whereas 
atypical hyperplasias are associated with a fourfold to fivefold increase in breast cancer risk. 
There are many clinical factors which appear to modify the risk associated with these lesions, 
including the time since biopsy, menopausal status, and family history of breast cancer. Recent 
studies have begun to evaluate the potential role of biologic, molecular, and genetic markers in 
assessing breast cancer risk in patients with benign breast disease.  New insights into benign 
breast disease and breast cancer risk will be derived from clinicopathologic follow-up studies, 
epidemiologic studies, and molecular and genetic studies(107) 
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1.6. Mammographic Density 
It is clear in studies that the risk of breast cancer is higher in those women with dense breasts, 
which will be discussed in greater detail below.  Factors which increase breast density include 
hormone therapy (HT), smoking, and family/genetic trends.  As women age or pass through 
menopause, fatty tissue replaces glandular tissue therefore decreasing breast density.  
Additionally, greater body mass index (BMI) generally equates with less breast density.  
Potential etiologies of breast density include epithelial and stromal proliferation, sex hormone 
induced response by growth factors, and DNA damage(3, 5, 6, 11, 14, 21, 52, 117, 121).  Lastly, 
in the PEPI study, mammographic density and bone mineral density (BMD) were reported to be 
positively associated in women who had not recently used exogenous hormones(42). 
 
1.7. Diet/Alcohol 
Generally, it has been difficult to explain the relationship between diet and breast cancer risk.  In 
a meta-analysis of papers published up until July 2003 including case-control and cohort studies, 
the association of dietary fat and breast cancer was evaluated.  A total of 45 risk estimates for 
total fat intake was obtained.  The summary relative risk, comparing the highest and lowest 
levels of intake of total fat, was 1.13 (95% CI: 1.03-1.25). Cohort studies (N=14) had a summary 
relative risk of 1.11 (95% CI: 0.99-1.25) and case-control studies (N=31) had a relative risk of 
1.14 (95% CI 0.99-1.32). Significant summary relative risks were also found for saturated fat 
(RR, 1.19; 95% CI: 1.06-1.35) and meat intake (RR, 1.17; 95% CI 1.06-1.29). Combined 
estimates of risk for total and saturated fat intake, and for meat intake, all indicate an association 
between higher intakes and an increased risk of breast cancer. Case-control and cohort studies 
gave similar results(17). 
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With respect to alcohol intake, the picture is clearer with a strong linear relationship 
indicating an increased risk with alcohol intake.  In a pooled analysis of 6 prospective studies 
conducted in Canada, the Netherlands, Sweden, and the United States the risk of invasive breast 
cancer associated with total and beverage-specific alcohol consumption was evaluated. In a total 
of 322,647 women followed for up to 11 years, including 4,335 participants with a diagnosis of 
incident invasive breast cancer, the risk increased linearly with intake, and the pooled 
multivariate relative risk for an increment of 10 g/d of alcohol (about 0.75-1 drink) was 1.09 
(95% CI, 1.04-1.13). This association did not appear to be modified by other factors(110).  
Similarly, Ellison et al(47) reported results from a meta-analysis of over 40 epidemiologic 
studies which suggested a 21% increase in breast cancer risk with an intake of 24 g of alcohol 
per day.  Potential mechanisms include effect on steroid hormone production, insulin growth 
factor-1(IGF-1), generation of reactive oxygen radicals, lipid peroxides, acetaldehyde or perhaps 
interaction with low folate levels. Additionally, it is postulated that that increased risk of breast 
cancer is related to increased estrogen and androgen levels(109).  Among women who consume 
alcohol regularly, reducing alcohol consumption is a potential means to reduce breast cancer 
risk(110). 
 
1.8. Anthropometry 
Weight, height, and BMI associations with breast cancer risk have been noted. HT has been 
shown to modify the association between body weight and breast cancer risk, with the exception 
of the Cancer Prevention Study-II, few studies are sufficiently large to examine the risk of breast 
cancer associated with BMI and weight gain separately among current HT users and 
nonusers(51).  Additionally, variations are noted among pre- and postmenopausal women.  
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Among premenopausal women, an inverse relationship between baseline weight and BMI and 
breast cancer risk was evident in a pooled analysis from seven prospective studies, while a 
positive relationship was noted among postmenopausal women(118).  In a study of 62,756 
postmenopausal women in the Cancer Prevention Study-II Nutrition Cohort with 1,934 incident 
breast cancer cases, the association of BMI and adult weight gain (since age 18 years) with 
breast cancer risk was stratified by HT use. Total adult weight gain strongly predicted breast 
cancer risk among former and never HT users (P for trend < 0.0001). Weight gain of 21–30 
pounds was associated with a rate ratio of 1.4 (95% confidence interval 1.1–1.8); rates doubled 
among women gaining >70 pounds compared with women who maintained their weight within 5 
pounds of their weight at age 18.  Among current HT users, no association was seen between 
breast cancer and either BMI or weight gain(51). 
 
1.9. Endogenous Hormone Factors 
Exposure to endogenous estrogen and its role as a risk factor for breast cancer has been described 
by many via the natural female processes of menarche and menopause. Menarche before age 12 
yields a RR of 1.0 compared to menarche at age greater than 15 where the RR is 0.77.  
Menopause occurring after age 55 yields a two-fold increase in breast cancer compared with 
those who undergo menopause before age 45(85).  Additionally, menarche before age 12 in 
combination with later menopause leads to a presumed increase in estrogen exposure, thereby 
increasing breast cancer risk(67).  Furthermore, as early as 1956, it was observed that women 
who underwent bilateral oophorectomy before their natural menopause hadreduced breast cancer 
risk(79).  
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 Similarly, the protective effect of pregnancy is apparent in those women who give birth to 
their first child before age 20 where the risk is reduced two-fold compared to women who give 
birth to their first child after age 30.  Further risk reduction is noted if a second birth occurs at an 
early age as noted in a large population-based cohort study(126)and case-control study(33).  
However, it is felt that the mechanism of protection cannot solely be explained by exposure to 
endogenous hormones and may be related to the direct effect on breast tissue.  In mouse models 
where early pregnancy was induced, it was noted that the breast glands became fully 
differentiated which may be protective against carcinogens (Presentation by Mary Daly). 
 
1.10. Exogenous Hormones 
1.10.1   Oral Contraceptives (OC) 
A meta-analysis in 1996 evaluated 54 epidemiologic studies consisting of 53,297 breast cancer 
cases and 100,239 controls.  In current users of oral contraceptives, there was a RR of 1.24 of 
developing breast cancer compared to never users.  This increased risk was seen for up to 10 
years after use, and family history of breast cancer did not appear to impact risk(40).  In a 
retrospective cohort study(54) of sisters and daughters of women with breast cancer [ever users 
of (compared with never users)] had a threefold increase in breast cancer risk.  However this 
increased risk was only noted in those who took OC before 1975 when hormone concentrations 
were higher(20).   Thus, the association between women with a family history of breast cancer 
and OC use remains unclear. 
1.10.2    Hormone Replacement Therapy (HT) 
It is widely accepted that estrogen plays a role in the development of breast cancer(37). Before 
menopause, estrogen is produced primarily by the ovaries. After menopause, estrogen is 
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produced endogenously by the aromatization of androgens in fat tissue. The primary source of 
exogenous estrogens in postmenopausal women is HT.  In the past, HT was generally prescribed 
to reduce symptoms associated with menopause, such as hot flashes and vaginal dryness(76).  
Subsequently, HT was used to reduce the risk of osteoporosis(76), although with the availability 
of agents specific for the prevention of osteoporosis, HT is generally used for symptoms related 
to the deficit in estrogen and progesterone .  In a national survey, with a representative cohort 
that was followed from the mid 1970s until 1992, approximately 45% of women had used HT, 
and about 43% of ever-users had been on HT for at least 5 years(19). 
Compelling data linking HT to postmenopausal breast cancer comes from a recent 
collaborative re-analysis of 51 epidemiologic studies, consisting of 53,865 postmenopausal 
women(8).  In that study, 33% of the women had used HT at sometime, and 34% of ever-users 
had used HT for 5 years or more.  Among current or recent (within 4 years) users, the relative 
risk of breast cancer increased by a factor of 1.02 (95%CI 1.01-1.04) for each year of use.  The 
relative risk for women who had used HT for at least 5 years was 1.35 (95%CI 1.21-1.49), an 
increase comparable to delaying menopause for an equivalent period. Interestingly, the relative 
risks of breast cancer associated with HT use decreased with increasing body weight, which is 
consistent with data from the Nurses Health Study(19, 65) and the Breast Cancer Demonstration 
Project(106). This is the opposite of the normal association between BMI and breast cancer risk, 
namely an increase in BMI is associated with an increase in breast cancer risk.  Therefore, it 
appears that HT modifies the association between BMI and risk of breast cancer.  Finally, 
combination estrogen-progestin regimens may increase breast cancer risk beyond that associated 
with estrogen only(106). 
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In the Women's Health Initiative, a randomized controlled primary prevention trial 
(planned duration, 8.5 years) in which 16,608 postmenopausal women aged 50-79 years with an 
intact uterus at baseline were recruited by 40 US clinical centers in 1993-1998, the data and 
safety monitoring board recommended stopping the trial of estrogen plus progestin vs placebo 
after a mean of 5.2 years of follow-up because the test statistic for invasive breast cancer 
exceeded the stopping boundary for this adverse effect and the global index statistic supported 
risks exceeding benefits. The estimated hazard ratio was 1.26 (95% CI 1.00-1.59) for breast 
cancer, with a total of 290 cases.  Absolute excess risks per 10000 person-years attributable to 
estrogen plus progestin were 8 more invasive breast cancers(129).  Additionally, while 
mammographic density was not routinely measured, Chlebowski et al reported that in the 
Women’s Health Initiative mammographic abnormalities occurred in 9.4% of the estrogen plus 
progestin group versus 5.4% in the placebo group, p <.001(34).   
Another study investigated the effects of specific types of HT on incident and fatal breast 
cancer.  In the Million Women Study, 1,084,110 UK women aged 50-64 years were recruited 
between 1996 and 2001.  Of those recruited 50% had used HT; 9364 incident invasive breast 
cancers and 637 breast cancer deaths were registered after an average of 2.6 and 4.1 years of 
follow-up, respectively.  Current users of HT at recruitment were more likely than never users to 
develop breast cancer (adjusted relative risk=1.66, 95% CI 1.58-1.75, p<0.0001) and die from it 
(RR=1.22, 95% CI 1.00-1.48, p=0.05). Past users of HT were, however, not at an increased risk 
of incident or fatal disease (RR=1.01, 95% CI 0.94-1.09 and RR=1.05, 95% CI 0.82-1.34, 
respectively). Incidence was significantly increased for current users of preparations containing 
estrogen only 1.30 (95% CI 1.21-1.40, p<0.0001), estrogen-progestin 2.00 (95% CI 1.88-2.12, 
p<0.0001), and tibolone 1.45 (95% CI 1.25-1.68, p<0.0001), but the magnitude of the associated 
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risk was substantially greater for estrogen-progestin than for other types of HT (p<0.0001). In 
current users of each type of HT, the risk of breast cancer increased with increasing total 
duration of use(89).  
Current use of HT and duration of use for former HT users, appears to be associated with 
an increased risk of breast cancer and the effect is substantially greater for estrogen-progesterone 
combinations than for other types of HT.   
 
1.11. Breast Density, Mammographic Screening Sensitivity and Breast Cancer Risk 
The histologic composition of the breast is reflected mammographically by density and 
parenchymal pattern.  The higher the fat content of the breast, the lower the radiologic density.  
Conversely, a high proportion of stroma or ductal and glandular tissue increases density (21, 52, 
94, 121).  At menopause, glandular and ductal tissue decreases and fibrous connective tissue is 
usually replaced by fat, explaining the decrease in mammographic density that occurs with 
age(2, 26, 57, 59, 74, 104, 119, 122, 123). Breast density is one factor shown to affect 
mammographic sensitivity(72, 81) and specificity(10, 50, 72, 81, 124, 127), and it is predictive 
of breast cancer risk(4, 13, 28, 29, 44, 53, 55, 58, 61, 71, 93, 104, 114, 122, 124, 127).   
In 1976, the first method to associate breast parenchymal patterns and breast cancer risk 
was proposed by Dr. John Wolfe.  His classification consisted of four patterns: N1-radiolucent 
breast, low risk, P1-linear radiographic densities or ductal prominence of lesser extent than P2, 
intermediate risk, P2-ductal prominence to a greater extent, intermediate risk, and DY-
radiographically dense, risk highest(14, 128).  Several studies have used Wolfe’s classification to 
measure breast cancer risk associated with mammographic density (Table 1).  In 3 cohort studies, 
the DY pattern was associated with an increased risk of breast cancer when compared with the 
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N1 pattern.  To date there have been several studies which have utilized Wolfe’s method to 
assess mammographic density.  A statistically significant increase in breast cancer risk was 
associated with increased density in thirteen of the fifteen cohort or case-control studies nested 
within cohort studies and fifteen of the nineteen case-control studies (OR 1.4-6.2)(14, 29, 36, 43-
45, 55, 71, 74, 75, 90, 102, 113, 115, 116, 125).  No association between breast cancer risk and 
density was found among six cross-sectional studies.  However, this may reflect a difference in 
the cancer detection time among the different parenchymal patterns(14-16, 18, 23-26, 30, 32, 44, 
49, 58, 64, 66, 73, 75, 88, 98, 100, 113, 115, 120, 124).   
 
Table 1-1: Wolfe’s studies   
                                    
Reference 
Type Subjects Results 
Brisson 1982 Case-control 408 Cancer 
1021 Controls 
RR DY vs N1 
1.9 (1.1-3.3) 
Chaudry 1983 Case-Control 104 Cancer 
937 Controls 
OR DY vs N1 
1.4 
Carlile 1985 Case-Control 706 Cases 
1412 Controls 
OR DY vs N1 
3.1 
Saftlas 1989 Case-Control 266 Cases 
301 Controls 
OR DY vs N1 
2.5 
Tabar & Dean 1982 Prospective 1857/21,157 screen 
31 incident cases 
RR DY vs N1 
Prevalent 2.9 
Incident 6.2 
Age 60+ 0.97 
Gravelle 1986 Prospective 4,044 women 
31 cancer 
RR DY vs N1 
4.4 (0.54-36.7) 
De Stavola 1990 Prospective 4,044 women 
69 cancer 
RR P2/DY vs P1/N1
1.7 (0.72-4.0) 
 
Despite the reported association between mammographic density and risk of breast 
cancer, there is great disparity among the studies with respect to the risk estimates when Wolfe’s 
classification is utilized.  It is believed that is largely due to the variation in observer assessments 
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of mammographic density.  Additionally, variations in study design have led to varying risk 
estimates. 
In an effort to reduce observer variability, various methods have been developed to 
quantitatively assess mammographic parenchymal patterns.  These methods encompass visual 
estimation of dense tissue, digitized images utilizing computer-assisted methods, and planimetry 
to measure the area of density within the total breast area.  To date a total of seventeen studies 
consisting of 7,410 cases and 14,421 controls (OR 1.2-6.0) have been published utilizing 
quantitative measurement (Table 2). 
Table 1-2: Quantitative Studies 
REFERENCE Type Method Results 
Boyd 1982 Case-control Estimation OR 6.0 (2.5-14.1) 
Brisson 1982 Case-control Estimation OR 5.4 (2.5-11.4) 
Brisson 1984 Case-control Estimation OR 4.4 (2.5-7.9) 
Brisson 1989 Case-control Estimation OR 4.6 (2.4-8.5) 
Wolfe 1987 Case-control Planimetry OR 4.3 (1.8-10.4) 
Saftlas 1991 N. Case-control Planimetry OR 4.3 (2.1-8.8) 
Boyd 1995 N. Case-control Estimation/computer OR 6.0 (2.8-13.0) 
Kato 1995 N. Case-control Planimetry OR 3.6 (1.7-7.9) 
Byrne 1995 N. Case-control Planimetry OR 4.3 (3.1-6.1) 
Lam 2000 N. Case-control BIRADS OR 4.5 (1.9-10.6) 
Van Gils 1999 N. Case-control Computerized 
(automated) 
OR 3.3 (1.5-7.2) 
Maskarinec/Meng 
2000 
Case-control Computerized 
(thresholding) 
OR 1.8 (1.1-3.0) 
Ursin 2003 Case-Control Computer-assisted OR 5.2 (1.7-16.1) 
Torres-Mejia 2005 Cohort Computer-assisted OR 3.5 (1.4-5.2) 
Thomas  2002 Case-Control Planimetry OR 4.4 (3.0-6.7) 
Maskarinec 2005 N. Case-Control Computer-assisted OR 1.2 (1.11-1.24) 
 
In both case-control(23, 30, 32, 49, 103) and cohort studies(55, 90, 113, 115), increased 
breast density as determined by Wolfe’s method has been associated with increased breast cancer 
risk (ORs ranging from 1.4-6.2).  Similarly, quantitative methods have shown an increased 
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association (ORs ranging from 2.0-3.8)(26) (12, 23, 25, 29, 29, 71, 103).  Studies using both 
methods have verified these findings and indicate that quantitative methods are more strongly 
associated with breast cancer risk than Wolfe’s method(23, 25, 26, 26).   
In a recent analysis, Brisson and colleagues sought to compare Wolfe’s method with 
percent density to determine if there was any added benefit when using both to determine density 
and subsequent breast cancer risk.  They looked at 3 case-control studies(23) (25, 26)for a total 
of 1060 newly diagnosed unilateral cases and 2352 controls who had undergone a routine 
screening mammogram.  The percent density was scored in categories and the original four 
categories were utilized for Wolfe’s method.  When comparing percent density of 85% or greater 
to women with zero density, there was a 5-6 fold increase risk of breast cancer.  However, with 
Wolfe’s method, only a 2-3 fold increase was noted in women with P2 or DY compared to N1 
patterns.  Additionally, among those women with P2 or DY, the RR varied greatly with percent 
density.  Conversely, there was little variation in the RR with the corresponding Wolfe pattern 
when given a percent density value(22). 
 
1.12. Factors that affect breast density 
   1.12.1 Age and Menopausal Status 
Typically, breast density decreases with postmenopausal status and increasing age(71).  
However, Byrne et al(29) found a greater effect of breast density on breast cancer risk in 
postmenopausal women OR 5.8 (95% CI 3.0-11.3) than in  premenopausal women OR 3.8 (95% 
CI 2.3-6.2).  Similarly, Boyd et al(12) found a higher risk in women ages 50-59 with a RR 7.1 
(95% CI 2.0-25.5) than in to women ages 40-49 RR 6.1 (95% CI 1.5-24.2).  The overlap in the 
CIs indicates that the association between breast density and cancer risk may not depend on 
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menopausal status or age(61).  Therefore, the association between breast density and age is most 
likely attenuated by other breast cancer risk factors(60). 
   1.12.2 Breast Density, and Breast cancer Risk 
HT has been shown to increase breast density in some, but not all women(9, 38, 48, 77, 78, 83, 
84, 86, 97, 99, 112), although this association is attenuated when HT is discontinued(9, 62, 95, 
105).   Exactly which women will experience an increase in risk with HT use remains unknown.  
Age may be one determining factor.  In one study of HT and breast density(111), there were no 
differences in breast density between HT users and non-users younger than age 55; in women 
over 55, the density was significantly greater in HT users.  HT regimen also affects breast 
density.  In the PEPI Trial(56), a double-blinded placebo controlled trial of HT, estrogen-
progestin users had a greater increase in breast density than estrogen only users (24% verses 
8%).  Similarly, McTiernan et al(86)reported an increase in mammographic density most notably 
from baseline to year one.  At year two the median increase in breast density percent persisted 
with a slight attenuation yielding an overall absolute increase in percent density of 4.9%.  Other 
studies(80, 83, 96)confirm this finding.  Additionally, the use of low dose HT(35) and 
transdermal HT(60) is associated with a smaller increases in mammographic density. 
 
1.13. Estrogen Metabolism 
Although the evidence linking estrogen and breast cancer is compelling(37), there is substantial 
evidence that the way estrogen is metabolized is associated with the risk of breast cancer.  
Estradiol metabolism is predominantly oxidative.  Estradiol is first (reversibly) converted to 
estrone, which is irreversibly converted to either 2- or 16α-hydroxy estrone in order to eliminate 
it from the body. Both 2- and 16α-OH estrone have estrogenic properties.   
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In both case-control studies(39, 63, 69, 70, 130) and a prospective study(87), higher 
levels of 16α-OH, the more active metabolite, are associated with increased risk. Conversely, 
higher levels of 2-OH, the less active and non-genotoxic metabolite, are associated with reduced 
risk(39, 63, 69, 130). Because the 2-OH and 16α-OH metabolites compete for a limited substrate 
pool, a rise in one pathway will reduce the amount of product in the competing pathway.  Thus, 
the relative activity of these two metabolic pathways (2:16α-OH) may be an endocrine 
biomarker for breast cancer risk. 
In a study of 513 nulliparous women(68), aged 17-35, lifestyle factors, such as ethnicity, 
body size, age at menarche, oral contraceptive use, smoking, vegetarian diet, coffee and alcohol 
consumption were evaluated with respect to the 2-OHE/16alpha-OHE ratio in plasma.  Among 
oral contraceptive users, there was a significantly lower 2-OHE/16alpha-OHE ratio than OC 
non-users, and among non-OC users, Asian women had significantly lower 2-OHE/16alpha-
OHE ratios than white women which remained after adjustment for age and day of menstrual 
cycle.  Among women not using oral contraceptives, the median 2-OHE/16alpha-OHE ratio in 
plasma was similar across all ethnic groups even after adjusting for age and menstrual cycle 
phase.  Daily coffee consumption was significantly positively correlated with 2-OHE/16alpha-
OHE ratios (r(s) = 0.18, P = 0.002) only among OC non-users.  The study findings suggest that 
the plasma 2-OHE/16alpha-OHE ratio is associated with constitutional factors and with 
modifiable lifestyle factors.   Additionally, modulation of estrogen metabolism to favor the less 
genotoxic metabolite 2-OH through physical activity was reported by Bentz et al(7). 
In a nested case-control study among10,786 women ages 35-69 years enrolled in the 
Hormones and Diet in the Etiology of Breast Cancer (ORDET) Study, 67 pre-menopausal cases, 
264 matched controls and 71 post-menopausal cases, 274 matched controls were evaluated for 
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the association of breast cancer risk with estrogen metabolism, specifically the ratio of 2-OH to 
16α-OH.  Among premenopausal women, a higher ratio of 2-OH to 16α-OH at baseline was 
associated with a reduced risk of breast cancer: women in the highest quintile of the ratio had an 
adjusted odds ratio (OR) for breast cancer of 0.58 (95% CI 0.25-1.34). The corresponding 
adjusted OR in postmenopausal women was 1.29 (95% CI 0.53-3.10). These results support the 
hypothesis that the estrogen metabolism pathway favoring 2-hydroxylation over 16alpha-
hydroxylation is associated with a reduced risk of invasive breast cancer risk in premenopausal 
women(91). 
In the Guernsey Study(87), a prospective study, postmenopausal women not using HT who went 
on to develop breast cancer over a 19-year period had about a 15% lower 2:16α-OH urinary 
metabolite ratio compared to matched control subjects, although the results were not statistically 
significant.   However, not all studies have found a relationship between estrogen metabolite 
levels and breast cancer risk.  In a case-cohort study conducted by Cauley et al the 2-
OHE/16alpha-OHE ratio did not predict breast cancer risk(31). 
   1.13.1 Estrogen Metabolism and Breast Density 
To date there has been one study that has evaluated the relationship between estrogen 
metabolism and breast density.  Riza et al evaluated the role of estrogen metabolites with respect 
to their relationship with high-density Wolfe mammographic parenchymal patterns (P2/DY).  
The study was nested within a large cross-sectional survey on determinants of mammographic 
patterns carried out in a population-based breast screening program in Northern Greece. Urinary 
levels of 2-OHE1 and 16(alpha)-OHE1 were measured in a random sample of 70 
postmenopausal women with P2/DY mammographic patterns and in a random sample of 70 
women with N1 mammographic patterns, individually matched to the P2/DY women on year of 
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birth, years since menopause and date of urine collection. Women with a P2/DY pattern had 58% 
higher levels of 2-OHE1 (P = 0.002) and 15% higher levels of 16α-OHE1 (P = 0.37) than those 
with an N1 pattern. The ratio of 2-OHE1:16α-OHE1 was 35% higher (P = 0.005) in women with 
a P2/DY pattern. Women in the highest one-third of this ratio were six times more likely to have 
a P2/DY pattern than those in the lowest one-third after adjusting for potential confounders 
(prevalence odds ratio, 6.2; 95% CI, 1.7-22.9; test for linear trend, P = 0.002). These findings 
seem to suggest that a high, rather than a low, 2-OHE1:16α-OHE1 ratio may be associated with 
an increase in breast cancer risk in postmenopausal women(101). 
   1.13.2 Estrogen Metabolism, HT and the Risk of Breast Cancer 
The effect of secreted or administered estrogen depends on the balance between these metabolic 
pathways(132), and exogenous estrogens may alter this balance.  In particular, combined 
estrogen-progestin (E+P) regimens may cause a greater shift to the 16-OH pathway compared to 
estrogen-alone (E)(108).  This observation may explain in part the observed greater breast cancer 
risk observed with combined HT regimens beyond that observed with estrogens alone.   
 
1.14. Estrogen/Progesterone Receptors 
In a study by Cotterchio et al(41), the relationship between hormonal factors and estrogen 
receptor (ER) and progesterone receptor (PR) status was evaluated in two recent population-
based case-control studies. Breast cancer cases, ages 25-74 years diagnosed 1995-1998, were 
sampled from the Ontario Cancer Registry.  Controls were frequency-matched to cases within 5-
year age groups.  ER/PR data was available for 87% of the breast cancer cases.  Significant 
differences were observed in the risk factor profiles for ER+PR+ and ER-PR- breast cancer.  
Among premenopausal women, late age at menarche was only associated with a reduction in 
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ER+PR+ breast cancer risk; obesity was associated with an increased ER-PR- and decreased 
ER+PR+ cancer risk; and the association between alcohol intake and breast cancer risk was 
heterogeneous across ER/PR subgroups, although the direction varied across the levels of 
alcohol intake. Among postmenopausal women, there were no statistically significant differences 
observed in the risk factor profiles for ER+PR+ and ER-PR- breast cancer.  In a report by Ziv et 
al(131), high mammographic density was associated with an increased risk of ER-positive and 
ER-negative breast cancers.   
Evidence suggests hormonal factors may be more strongly associated with ER+PR+ than 
ER-PR- breast cancer risk.  Measures of estrogen metabolism have not been studied in relation to 
type of breast cancer, that is, breast cancer according to receptor status.     
 
1.15. Research Questions 
First: What are the determinants of serum sex hormones and estrogen metabolite levels in 
postmenopausal women in the Study of Osteoporosis and Fractures (SOF)? In the first article, we 
evaluated the relationship between estrogen metabolite levels and breast cancer risk factors, 
independent of sex-steroid hormones, in an attempt to provide insight into the underlying 
biologic mechanisms. 
Second: Is there a relationship between breast density and estrogen metabolism?  Breast 
density and measures of estrogen metabolism (blood and urinary levels of 2-hydroxyestrone (2-
OH) and 16alpha-hydroxyestrone (16α-OH)) have been studied in relation to breast cancer risk. 
In the second article, we endeavored to characterize the relationship between breast density and 
the serum concentrations of two major estrogen metabolites (2-OH and 16α-OH) in pre- and 
post-menopausal women without breast cancer.   
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Third: What is the relationship between breast density, estrogen metabolism and the risk 
of breast cancer?  The objective of the third paper was to compare the joint distribution of 
density and metabolites between cases and controls and calculated associated measures of risk 
association, unadjusted and adjusted for other traditional or conventional breast risk factors. 
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2.1. Abstract 
BACKGROUND:  Estrogen metabolites and sex-steroid hormones have been shown to be 
related to the risk of breast cancer.  In the current report, we evaluated the relationship between 
estrogen metabolite levels and breast cancer risk factors, independent of sex-steroid hormones, in 
an attempt to provide insight into the underlying biologic mechanisms.  
METHODS:  We analyzed data from 282 randomly selected women without breast cancer, 
enrolled in the Study of Osteoporotic Fractures (SOF), a longitudinal cohort study.   
RESULTS: 16 alpha-hydroxyestrone (16α-OH) was positively associated with body mass index 
(BMI) (r=0.162), estradiol (r=0.171), and testosterone (r=0.158) and inversely associated with 
sex hormone binding globulin (SHBG) (r=-0.165), all (p=0.01).  However, these associations 
were not significant in multivariate analyses that controlled for the serum sex-steroid hormone 
concentrations (total estradiol, total testosterone, SHBG).  Neither 2-hydroxyestrone (2-OH) nor 
the 2:16 ratio was related to the sex-steroid hormones.  Women who reported a surgical 
menopause were significantly more likely to have higher levels of 16α-OH (OR=(tertile 3 vs 
tertile 1) 7.37, 95% Confidence Interval (CI) 2.20-24.70) but there was no difference in 2-OH 
levels.   
CONCLUSION:  Except for BMI, 16α-OH, and surgical menopause, we did not see 
associations between the estrogen metabolites and the traditional risk factors.  Control for 
substrate hormones eliminated the BMI association, but not the association with type of 
menopause.  While it appears that the substrate hormone levels appear to mediate the association 
between BMI and 16α-OH, the apparent lack of residual association between BMI (and other 
risk factors) with 16α-OH or 2-OH suggests that inter-individual differences in hormone 
metabolism, per se, are insensitive to external factors. 
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 2.2. Introduction 
Although the evidence linking estrogen and breast cancer is compelling(9), there is substantial 
evidence that estrogen metabolites may be associated with the risk of breast cancer.  Estradiol 
metabolism is predominantly oxidative.  In order to eliminate estradiol from the body it is first 
(reversibly) converted to estrone, then is irreversibly converted to either 2-hydroxyestrone (2-
OH) or 16alpha-hydroxyestrone (16α-OH).  Both 2-OH and 16α-OH have estrogenic properties.   
In case-control studies(10, 15, 18, 31) and a prospective study(22), higher levels of 16α-
OH, believed to be the more active and genotoxic metabolite, are associated with increased 
breast cancer risk. Conversely, higher levels of 2-OH, the less active and non-genotoxic 
metabolite, are associated with reduced risk(10, 15, 18, 31). Because enzymes responsible for the 
conversion of 2-OH and 16α-OH metabolites compete for a limited substrate pool, increased 
activity in one pathway will reduce the amount of product in the competing pathway.  However, 
not all studies have found a positive association.  We measured serum estrogen metabolites in a 
case-cohort study of 272 women with confirmed incident breast cancer and 291 random controls.  
The risk of breast cancer in women with the highest quartile of the 2:16α-OH ratio compared 
with those in the lowest quartile was 1.17 (95% confidence interval (CI)= 0.73-1.87) and 
therefore did not support the hypothesis that the ratio of 2-OH to 16α-OH predicts breast cancer 
risk.  Thus, the relative activity of these two metabolic pathways (2:16α-OH) as an endocrine 
biomarker for breast cancer risk deserves further study. 
This metabolic pathway appears to vary by ethnicity and various lifestyle factors.  In a 
study of 513 nulliparous women, aged 17-35, lifestyle factors (ethnicity, body size, age at 
menarche, oral contraceptive (OC) use, smoking, vegetarian diet, coffee, alcohol consumption) 
were evaluated with respect to the 2-OH:16α-OH ratio in plasma.  There was a significantly 
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 lower 2-OH:16α-OH ratio in OC users versus non-users, and Asian OC users had significantly 
lower 2-OH:16α-OH ratios than white OC users which remained after adjustment for age and 
day of menstrual cycle.  No significant difference was noted across ethnic groups in non-users.  
Daily coffee consumption was significantly positively correlated with 2-OH:16α-OH ratios (r(s) 
= 0.18, P = 0.002), but only among OC non-users.  The study findings suggest that the plasma 2-
OH:16α-OH ratio is associated with constitutional factors and with modifiable lifestyle 
factors(17). 
In the current manuscript, we examined the relationship of breast cancer risk factors (age, 
weight, body mass index, age at menarche, age at first birth, age at menopause, family history of 
breast cancer, history of fibrocystic disease, alcohol consumption), additional lifestyle factors 
(smoking, exercise), sex steroid hormones, and estrogen metabolites in breast cancer-free 
postmenopausal women at risk from the the Study of Osteoporotic Fractures (SOF)cohort(7).  To 
our knowledge, the association of sex-steroid hormones, estrogen metabolites, and breast cancer 
risk factors has not been reported.  The long range goal of the analysis is to gain a better 
understanding of the underlying biologic mechanisms guiding the relationship between the active 
hormones, metabolites, and breast cancer risk factors.  
 
2.3. Materials and Methods 
2.3.1 Study Population 
All women in this study were participants in SOF, a longitudinal study that evaluated risk factors 
for osteoporosis and falls in 9,704 White women age 65 and older.  They were recruited from 
1986-1988 using population-based lists in Baltimore, MD, Pittsburgh, PA, Minneapolis, MN, 
and Portland, OR.  The complete study design and methodology have been described in previous 
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 publications(11).  Previous case-cohort studies within SOF have examined estrogen metabolites 
and breast cancer risk(7) and the role of sex hormones and breast cancer(6, 8).  Breast cancer 
free controls (over 8.7 years) were randomly chosen using a case-cohort approach.  Women with 
prevalent breast cancer or reported use of hormone therapy at baseline were excluded (7).  We 
included only those cancer free controls who participated in the estrogen metabolite study and 
who also had available sex serum hormones.  Analyses included nine women missing estradiol, 
one missing testosterone, and one missing testosterone and SHBG for a total sample N=282.  
The institutional review boards at each institution approved the study and informed consent was 
obtained from all women.  
2.3.2 Data Collection 
All women underwent an interview and were given a self-administered questionnaire at each bi-
annual clinic visit.  Reproductive history and anthropometric measurements were obtained at 
baseline via the interview and questionnaire process and were utilized in this analysis.  Breast 
cancer risk factors included age at menopause, age at menarche, age at first full term birth, 
parity, weight, body mass index (BMI) and alcohol use(drinks per week).  Categorical variables 
included type of menopause (surgical/natural), ever pregnant (yes/no), family history of breast 
cancer (yes/no), history of benign breast disease (yes/no), walks for exercise (yes/no), past 
estrogen use (yes/no), and ever smoke (ever/never).   
2.3.3 Laboratory Measurements 
Serum was collected at baseline and was used to assess total estradiol, total testosterone, sex 
hormone binding globulin (SHBG), 2-OH, and 16α-OH.  All women were instructed to adhere to 
a fat free diet the evening before and the morning of the blood draw to minimize lipemic sera.  
The blood was drawn between 8:00 AM and 2:00 PM and was frozen to –20oC.  All samples 
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 were shipped to a central repository within 2 weeks where they were stored at –190oC until 
assay.   
The 2-OH and 16α-OH estrogen metabolite levels were measured by Immuna Care 
Corporation (Bethlehem, PA) with the ESTRAMET 2/16 enzyme immunoassay kits (ELISAs) 
using blinded serum samples(7, 20).  The ESTRAMET 2/16 ELISA was previously validated 
against gas-chromatography-mass spectroscopy (GC-MS) in pooled serum with known amounts 
of 2-OH and 16α-OH(7).  The sensitivity of the 2-OH and 16α-OH assays is approximately 20 
pg/mL and 10 pg/mL, respectively.  Variability of within-assay duplicates for positive control 
sera for these serum samples were less than 5% and the between-assay variability was less than 
15% for both estrogen metabolite assays.  To assess reproducibility serum levels of 2-OH and 
16α-OH from 25 postmenopausal women measured in blind duplicate in different batches were 
measured yielding a correlation of r=.98(7).   
The Endocrine Sciences (Calabassas, CA) and Corning Nichols Institute (San Juan 
Capistrano, CA) were utilized for analysis of the sex-steroid hormones.  Total estradiol was 
measured using liquid-liquid organic extraction, column chromatography and radioimmunoassay 
(RIA), (intra- and inter- assay variability, 4-12% and 6-12%, respectively; sensitivity of 2 
pg/ml)(8).   Total testosterone was measured by using radioimmunoassay with chromatographic 
purification (coefficient of variation for intra-assay and total assay, 6% to 14% and 5% to 13%, 
respectively; sensitivity, 0.03 nmol/L).  Sex hormone-binding globulin was measured by using 
radioimmunoassay (coefficient of variation for intra-assay and total assay, 7% and 7.8% 
respectively; sensitivity, 5.0 nmol/L) (8). 
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 2.4. Statistical Analysis 
Demographic characteristics of the study sample were compared to the remainder of the SOF 
population (Table 1) using t-tests for independent samples (continuous variables) and chi-square 
test (categorical variables).  Estrogen metabolite levels and sex-steroid hormones were 
logarithm-transformed to normalize the values for all analyses.  All hormone levels were within 
the assay range.  Log transformed values were back-transformed to present the geometric means 
in their initial units of measure.  Pearson correlation coefficients were calculated to determine 
significant relationships between sex steroid hormones, estrogen metabolite levels, 
anthropometric measurements, and reproductive factors.  Variables with a significant (p-value 
<0.10) univariate association with target hormone levels were further evaluated with logistic 
regression.  We used logistic regression to examine the independent association between the 
level of a particular estrogen metabolite and various factors including hormones, binding protein, 
and behavioral/reproductive breast cancer risk factors.  Analyses were conducted with a base 
model consisting of standardized log transformed estradiol, testosterone, and SHBG.  Age, BMI, 
and other statistically significant variables (p <0.10), identified in univariate analyses were added 
to the base model singly, to evaluate the metabolite levels in mid versus low tertile as well as 
high versus low tertile.  The Hosmer-Lemeshow goodness of fit was assessed for all models.  All 
tests of statistical significance were two-tailed.  Probability values of < 0.05 were considered 
statistically significant.     
All analyses were conducted using SPSS for windows, version 11.0. 
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 2.5. Results 
Descriptive characteristics of the study population compared to the remainder of the SOF cohort 
are shown in Table 1.   Women included in this study ranged in age from 65-86 (mean 71.49) 
and 18.6% were nulligravid.  Among parous women, the average age at first birth was 25 years 
(SD=4.8).  The study sample was essentially identical to the remaining SOF participants.  
Correlations between the hormones and estrogen metabolites are shown in Table 2.  All 
were statistically significant, with the exception of the correlations involving the primary 
hormones and 2-OH and the 2:16 ratio.  Among the estrogens, SHBG was negatively correlated 
with estradiol (r=-0.287, p=0.01) and 16α-OH (r=-0.165, p=0.01).  The 16α-OH metabolite 
levels positively correlated with estradiol and testosterone whereas the 2-OH was not correlated 
with estradiol or SHBG.  Additionally, the 2:16 ratio correlated with its components 2-OH and 
16α-OH, but not estradiol (r=-0.076, p=0.213), SHBG (r=0.058, p=0.337), or testosterone (r=-
0.092, p=0.126). 
In univariate analyses, weight, BMI, and surgical menopause were found to be 
significantly associated with 16α-OH levels (Tables 3 and 4).  However, the associations 
between weight and 16α-OH and BMI and 16α-OH disappear in multivariate analyses 
controlling for estradiol, testosterone, and SHBG.  With the exception of surgical menopause, no 
variables were significantly associated with either the 2-OH levels (Tables 3 and 4) or 2:16 ratio 
(Tables 3 and 4).   
In logistic regression models, a one standard deviation unit increase in log transformed 
testosterone increased the likelihood of being in the high tertile vs low tertile 16α-OH by 1.62 
fold while a one standard deviation unit increase in SHBG resulted in a decreased likelihood 
(OR=0.64) of having a 16α-OH in the high vs the low tertile (Table 5).  Surgical menopause 
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 increased the likelihood of high tertile vs low tertile 16α-OH by 7-fold (OR= 7.37, p<0.001). 
The geometric mean 16α-OH level in women with surgical menopause was 14% greater than 
women with natural menopause (254 pg/mL versus 222 pg/mL, p < 0.05).  After adjusting for 
estradiol, testosterone, and SHBG, the geometric mean 16α-OH is 20% higher in women with 
surgical menopause compared to those with natural menopause (263 pg/mL vs 220 pg/mL) (95% 
CI ratio of 9-33% (p < 0.05)).   
In multivariate models, no factors were found to be associated with 2-OH levels (Table 
5).   
 
2.6. Discussion 
We observed significant associations between the sex-steroid hormones and estrogen metabolite 
levels.  The relationship between weight and 16α-OH and BMI and 16α-OH were statistically 
significant in univariate analyses.  However, in multivariate analyses, these relationships 
disappeared once we controlled for the sex-steroid hormones.  In general, there were no 
significant relationships between the putative breast cancer risk factors and the 2-OH levels and 
the 2:16 ratio.    
Previous studies have focused primarily on differences in estrogen metabolism across 
case-control status rather than the relationship between the estrogen metabolites and lifestyle and 
reproductive factors(15, 18, 25, 30, 31).  Additionally, there is a paucity of data incorporating 
serum estrogen metabolite levels along with sex-steroid hormones as potential mediators of 
breast cancer risk.     
Prior studies have focused on breast cancer risk relationships involving either 
reproductive and lifestyle factors, sex-steroid hormones, or lastly estrogen metabolites.  While 
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 each of these factors (risk factors, sex-steroid hormones, estrogen metabolites) singly have been 
implicated in increased breast cancer risk, the interaction between the circulating hormones, 
estrogen metabolites, and breast cancer risk factors remains unclear.  This dataset allowed the 
opportunity to examine the relationship among these factors in an attempt to better understand 
the biologic model at work.               
A significant positive relationship was seen between 16α-OH and testosterone and 16α-
OH and estradiol, while a significant inverse relationship was noted between 16α-OH and 
SHBG. Estradiol, testosterone and SHBG have been associated with breast cancer risk.  In a 
reanalysis of nine prospective studies, testosterone has been associated with a 2-3 fold increase 
in relative risk of breast cancer for women with levels in the highest versus lowest quintile(27), 
with estrogen receptor (ER) positive breast cancer(3), and most recently with breast cancer 
recurrence(4).  Evidence increasingly supports the relationship between estrogen and breast 
cancer risk(10, 29) with a 3.6-fold increased risk of breast cancer in those with a high serum 
concentration versus low concentration of bioavailable estradiol in a previous SOF analysis(8).  
In a follow-up report with a larger sample, the association between estradiol and breast cancer 
was not significant after controlling for testosterone(3).  Prospective studies have identified an 
inverse relationship between SHBG and breast cancer risk(12, 14, 28).  
In univariate analyses, we observed significant relationships between 16α-OH weight, 
and BMI.  Aromitazation of androstenedione to estrone in fatty tissue has been implicated as the 
source of estrogen and contributes to the increased breast cancer risk in women who are obese or 
experience weight gain throughout life(8, 21, 26).  In our analyses, the association between 
weight and BMI disappeared after controlling for estradiol, SHBG, and testosterone suggesting 
that obesity is influencing 16α-OH through mechanisms independent of aromitazation.  In a 
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 study of 62,756 postmenopausal women in the Cancer Prevention Study-II Nutrition Cohort with 
1,934 incident breast cancer cases, the association of BMI and adult weight gain (since age 18 
years) with breast cancer risk was reported.  Additionally, the analyses were stratified by 
hormone therapy (HT) use. Total adult weight gain strongly predicted breast cancer risk among 
former and never HT users (P for trend < 0.0001). Weight gain of 21–30 pounds was associated 
with a rate ratio of 1.4 (95% confidence interval 1.1–1.8); rates doubled among women gaining 
>70 pounds compared with women who maintained their weight within 5 pounds of their weight 
at age 18.  Among current HT users, no association was seen between breast cancer and either 
BMI or weight gain(13).  Additionally, we know that obesity has been associated with 
testosterone(6)and body weight(19) in women.   In our analyses, we observed a borderline 
relationship between testosterone and BMI (p=0.069).     
In our analyses, we found no relationships between traditional risk factors (age, age at 
menarche, age at first birth, age at menopause) and the estrogen metabolite levels.  This may 
have reflected the small sample size but it is possible that these factors influence breast cancer 
through mechanisms that do not involve estrogen metabolites.   
We found a significant positive relationship between surgical menopause and the 16α-
OH metabolite, independent of estradiol, testosterone, and SHBG.  Women who had a surgical 
menopause had seven times the odds of having a 16α-OH level in the high versus low tertile 
(OR=7.37, p<0.001).  Indications for surgical menopause often include endometriosis, 
premenstrual syndrome, and fibroids.  Many of these processes may result from abnormal 
hormone regulations, including estrogen(2, 5, 23).  In a study of 15,844 women, a non-
significant increase in breast cancer risk was noted in women who underwent gynecologic 
surgery for endometriosis(24).  It has also been postulated that the exposure to estrogen between 
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 menarche and first live birth is the critical period as breast tissue is most actively copying DNA 
and cells dividing during that life phase(1, 16).  Hence, the higher 16α-OH associated with 
surgical menopause may reflect the underlying hormone dysregulation associated with the 
indication for the hysterectomy.   
This study has several strengths. The study population consists of well-characterized 
women who were cancer free over an 8.5-year period.  Standardized data were collected 
independent of breast cancer outcomes and laboratory results.  Additionally, with an age range of 
65-86 (mean 71), this allows insight into an aged population that few studies can report.   
Limitations include the use of all white women limiting the ability to apply these results 
across diverse populations.  Self-administered questionnaires have the potential for recall bias.  
Lastly, issues with data include colinearity of hormones and a relatively small sample size.   
These same factors (weight, BMI, estradiol, testosterone, SHBG, and surgical 
menopause) were not related to 2-OH nor to the 2:16 ratio.  It is believed that the 2-OH levels 
can be increased by changes in dietary habits, thereby increasing the 2:16 ratio and decreasing 
the risk of breast cancer.  What remains unclear is whether or not these lifestyle changes can alter 
the 16α-OH and subsequently result in decreased 16α-OH levels, increased 2:16 ratio and 
decreased breast cancer risk.   
Except for BMI, 16α-OH, and surgical menopause, we did not see associations between 
the estrogen metabolites and the traditional risk factors.  Control for substrate hormones 
eliminated the BMI association, but not the association with type of menopause.  While it 
appears that the substrate hormone levels appear to mediate the association between BMI and 
16α-OH, the apparent lack of residual association between BMI (and other risk factors) with 
16α-OH or 2-OH suggests that inter-individual differences in hormone metabolism, per se, are 
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 insensitive to external factors. The strong relationship between surgical menopause and higher 
levels of 16α-OH deserves further attention.  It is unknown if this reflects the indication for the 
hysterectomy or the lack of ovaries post-menopausally.   
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Table 2-1:  Baseline characteristics of the SOF population and study subjects sampled from SOF 
(excluding participants with prevalent breast cancer or self-reporting HT use) 
  
N 
 
Sample(SD) 
 
N 
 
SOF (SD) 
 
p-value¶
      
Mean age in years 279 71.49 (4.82) 7419 71.80 (5.33) 0.08 
Mean body weight in kg 279 67.47 (12.01) 7291 67.51 (12.74) 0.96 
Mean body mass index (kg/m2) 279 26.65 (4.50) 7291 26.72 (4.76) 0.81 
Mean age at menarche in years 259 13.13 (1.58) 6619 13.07 (1.48) 0.58 
Mean age at first birth in years† 213 25.03 (4.84) 5541 25.33 (4.95) 0.40 
Mean age at menopause in years 232 48.88 (4.79) 6082 47.89 (5.78) 0.10 
% with Surgical menopause  241 11.20 6323 11.05 0.92 
% Nulliparous  279 18.64 7288 16.56 0.37 
% with Family history of breast cancer  237 17.72 7570 15.22 0.37 
% with History of fibrocystic disease  262 11.83 6787 12.80 0.71 
% with Past estrogen use  273 31.14 7289 32.10 0.79 
Mean Alcohol (drinks/week) 279 1.48 (3.04) 7291 1.90 (4.18) 0.10 
% Current smoker  278 6.83 7265 10.00 0.15 
% who Walk for exercise  279 54.84 7290 49.45 0.09 
SD=Standard Deviation  
†Among parous women 
HRT=Hormone Replacement Therapy 
¶t-test for continuous measures, chi-square for categorical measures; Statistical test based on comparison of SOF subjects 
sampled vs those not sampled 
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Table 2-2: Pearson Pairwise correlations involving serum-based sex steroid hormone and estrogen metabolite measures†
 Estradiol SHBG 2-OH 16α-OH 2:16 Ratio 
      
Testosterone 0.323* 0.160* 0.019 0.158* -0.092 
Estradiol  -0.287* 0.046 0.171* -0.076 
SHBG   -0.086 -0.165* 0.058 
2-OH    0.220* 0.661* 
16α-OH     -0.538* 
* Correlation is significant at the 0.01 level (2-tailed)    
SHBG=Sex Hormone Binding Globulin 
Sample of SOF participants (N=282)    
2-OH=2-hydroxyestrone 
16α-OH=16α-hydroxyestrone 
†Sample counts vary between N=272-282 due to missing values.  
 
Table 2-3: Simple and partial correlations between risk factor variables and estrogen metabolite measures  
(adjusted for log transformed estrogen, testosterone, and SHBG) 
Variable N 2-OH 16α-OH 2:16 Ratio 
  Simple 
Correlation 
Partial 
Correlation 
Simple 
Correlation 
Partial 
Correlation 
Simple 
Correlation 
Partial 
Correlation 
Age 282 0.054 0.081 0.058 0.081 0.013 0.081 
Weight 282 0.046 -0.019 0.122* -0.019 -0.055 -0.019 
Body Mass 
Index 
282 0.044 -0.014 0.162** -0.014 -0.093 -0.014 
Age at 
Menarche 
260 -0.116 -0.123 -0.061 -0.123 -0.065 -0.123 
Age at first 
birth 
214 -0.048 -0.039 0.062 -0.039 -0.049 -0.039 
Age at 
menopause 
235 0.048 0.005 -0.066 0.005 0.062 0.005 
Drinks/week 282 0.014 0.005 -0.024 0.005 -0.007 0.005 
*Correlation significant at the 0.05 level (2-tailed)   
**Correlation significant at the 0.01 level (2-tailed)           Abbreviations-refer to table 2 
 47 
Table 2-4:  Geometric mean 2-hydroxyestrone (2-OH),  16α-hydroxyestrone (16α-OH), 2:16-OH ratio according to breast 
cancer risk factors.  
Unadjusted and adjusted for estradiol, testosterone, and SHBG 
 
   2-OH 16α-OH 2:16 Ratio 
   Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted 
Variable  N Geometric 
Mean (pg/ml)
Geometric 
Mean (pg/ml)
Geometric 
Mean (pg/ml) 
Geometric 
Mean (pg/ml)
Geometric 
Mean (pg/ml) 
Geometric 
Mean (pg/ml) 
Menopause Natural 
Surgical 
234 
25 
170 
172 
166* 
199 
222* 
254 
220* 
263 
0.75 
0.67 
0.73* 
0.87 
Ever 
pregnant 
No 
Yes 
51 
218 
182 
167 
177 
168 
235 
224 
235 
224 
0.76 
0.74 
0.77 
0.73 
Family 
history of 
breast cancer 
Yes 
No 
41 
228 
168 
170 
163 
171 
218 
227 
217 
228 
0.75 
0.74 
0.71 
0.75 
History of 
fibrocystic 
breast disease 
Yes 
No 
31 
220 
181 
169 
166 
170 
221 
226 
220 
225 
0.82 
0.73 
0.73 
0.75 
Past estrogen 
use 
Yes 
No 
79 
190 
176 
167 
168 
171 
219 
229 
223 
227 
0.80* 
0.72 
0.73 
0.74 
Ever smoke Yes 
No 
76 
174 
169 
171 
173 
170 
231 
225 
230 
226 
0.72 
0.75 
0.75 
0.74 
Walks for 
exercise 
No 
Yes 
123 
146 
174 
167 
168 
171 
227 
225 
224 
228 
0.76 
0.73 
0.73 
0.75 
 
*p-value significant at the <0.05 (two-tailed) 
Abbreviations-refer to Table 2 
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Table 2-5:  Multiple logistic regression 
The odds of mid-tertile relative to low-tertile 2-hydroxyestrone (2-OH)/ 16α-hydroxyestrone (16α-OH) and the odds of high-
tertile relative to low-tertile 2-OH/16α-OH (95 % confidence interval) according to specified change in breast cancer risk 
factor values. 
 
Model 
 
Risk Factor Change 
Mid Tertile vs  
Low Tertile 
High Tertile vs  
Low Tertile 
2-OH  OR, (95% CI) OR, (95% CI) 
    
Base Model 1 S.D. Unit Estradiol 1.27 (0.89-1.82) 1.01 (0.72-1.42) 
 1 S.D. Unit Testosterone 0.97 (0.70-1.35) 1.18 (0.85-1.63) 
 1 S.D. Unit SHBG 0.90 (0.65-1.24) 0.76 (0.54-1.06) 
    
Base + Age 1 year of age  1.03 (0.96-1.10) 1.06 (0.99-1.12) 
    
Base + BMI 1 BMI unit 0.99 (0.91-1.07) 0.99 (0.91-1.06) 
    
Base + Nulliparity 
 
Never pregnant vs ever pregnant 1.18 (0.51-2.70) 0.56 (0.27-1.16) 
16α-OH    
    
Base Model 1 S.D. Unit Estradiol 0.97 (0.69-1.37) 1.00 (0.70-1.41) 
 1 S.D. Unit Testosterone 1.24 (0.90-1.72) 1.62 (1.13-2.32)* 
 1 S.D. Unit SHBG 1.10 (0.78-1.56) 0.64 (0.46-0.91)* 
    
Base + Age 1 year of age  0.99 (0.93-1.05) 1.05 (0.98-1.12) 
    
Base + BMI 1 BMI unit 0.99 (0.91-1.07) 0.96 (0.89-1.04) 
    
 
Base + Surgical Menopause Surgical vs Natural Menopause 1.13 (0.31-4.07) 7.37 (2.20-24.70)** 
 
CI=Confidence Interval     **significant at the 0.001 (two-tailed) level  
Tertile cutpoints 2-OH= 154 pg/mL and 188 pg/m/L; 16α-OH =201 pg/mL and 253 pg/mL *significant at the 0.05 (two-tailed) level 
S.D.=Standard deviation      OR=odds ratio, adjusted for all other factors included in the model.   
Abbreviations-refer to Table 2 
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 3.1. Abstract 
BACKGROUND:  Breast density and measures of estrogen metabolism (blood and urinary 
levels of 2-hydroxyestrone (2-OH) and 16alpha-hydroxyestrone (16α-OH)) have been studied in 
relation to breast cancer risk. In pre- and post-menopausal women without breast cancer, we 
endeavored to characterize the relationship between breast density and the serum concentrations 
of these two major estrogen metabolites. 
METHODS:  We measured breast density (area measure of visibly dense breast, expressed as a 
percentage of the total breast area on a standard two-dimensional mammogram) and serum 
concentrations of 2-OH and 16α-OH in 380 (124 pre- and 256 post-menopausal) women, 
including 283 pre- or post-menopausal women not currently taking post-menopausal hormone 
medications. All subjects lacked a diagnosis of breast cancer despite screening mammography or 
biopsy of suspicious breast abnormalities. 
RESULTS:  In all subjects (N=380), breast density correlated weakly with log-transformed 
serum concentrations of 16α-OH (Pearson correlation coefficient (ρ) = 0.10, p-value < 0.1; 
Pearson partial correlation coefficient adjusted for body mass index (BMI) and menopausal 
status-specific age quartile (adjusted ρ) = 0.13, p-value < 0.05) and with log-transformed serum 
concentrations of 2-OH (ρ = 0.13, p-value < 0.05; adjusted ρ = 0.09, p-value < 0.1). In subjects 
not taking post-menopausal hormone medications (N=283), partial correlations were similar in 
magnitude, 0.12 (p-value < 0.1) and 0.09 (p-value = not significant) for 16α-OH and 2-OH, 
respectively. Stratification according to menopausal status substantially reduced or eliminated 
associations between breast density and the estrogen metabolite concentrations.  
CONCLUSION: High serum concentrations of the 16α-OH and 2-OH correlated with breast 
density. The associations between the estrogen metabolites and breast density appeared 
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 independent of post-menopausal hormone medication use. However, statistical associations 
disappeared upon control for menopausal status. This pattern of association is consistent with 
two possibilities. First, serum estrogen metabolite concentrations and breast density may share 
common determinants that are related to the menopause. Or, estrogen metabolite changes, 
occurring as a consequence of menopause, may directly contribute to the menopause-associated 
declines in breast density. Determination of the menopause-specific cross-sectional associations 
between the serum estrogen metabolites and breast density may require larger studies, with 
sufficient numbers of pre- and post-menopausal women. 
Key Words: Breast Density, Estrogen Metabolism 
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 3.2. Introduction 
Breast cancer risk is higher in women with dense breasts(7, 8). Breast density may be a 
measurable manifestation of biological states or processes related to breast carcinogenesis. For 
example, breast cancer-relevant biological states and processes possibly associated with breast 
density may include sex hormone-induced breast epithelial and stromal cell hyper-
proliferation(1-3, 6, 7, 11, 24, 49, 50), growth factor expression(9, 14, 26), and DNA 
damage(31). Breast density clearly increases in women placed on post-menopausal hormones(4, 
19, 23, 36, 37, 39-41, 43, 44, 48), an exposure causally related to breast cancer(53). Other 
hormone-related factors associated with lower breast density include higher age, parity, and 
menopause(7, 34). However, breast density (expressed as a percentage of the total breast) 
decreases with higher body mass index (BMI)(8), a factor generally thought to increase post-
menopausal endogenous estrogen exposures as a consequence of the metabolic conversion of 
adrenal androgens in adipose tissue(31, 54). The lower breast densities observed in women with 
higher BMI might simply reflect a higher fat content in the breasts of relatively more obese 
women. 
In concert with the estrogen-breast cancer link(18), a body of evidence implicates specific 
estrogen metabolites with enhanced or reduced breast cancer risk. Specifically, estrogen 
metabolism in humans entails the formation of 2-hydroxyestrone (2-OH), 4-hydroxyestrone (4-
OH), and 16alpha-hydroxyestrone (16α-OH) from estrone. Relative to 2-OH, the 16α-OH 
product is estrogenic and genotoxic(54, 56). Because 2-OH and 16α-OH are complementary 
metabolic products derived from a fixed substrate pool, any genetic or environmental factor, that 
increases enzymatic production of one metabolite, can be expected to reduce enzymatic 
production of the alternative metabolite. Taking account of the estrogenicity and genotoxicity of 
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 16α-OH relative to 2-OH, investigators have postulated increased breast cancer risk in women 
with high blood or tissue levels of 16α-OH or in women who excrete relatively little 2-OH 
relative to 16α-OH. Although the epidemiologic evidence is not universally supportive(56), 
several case-control studies(21, 28, 28, 32, 33, 55) and at least one prospective study(42) are 
consistent with the hypothesized association between the estrogen metabolites and breast cancer 
risk. Notions regarding the effects of estrogen metabolites on breast cancer risk and notions 
regarding breast density as a biological measure of estrogen response create the justification for 
exploring and characterizing a possible causal association between the estrogen metabolites and 
breast density. 
To our knowledge, only Riza et al.(45) have reported on the relationship between the estrogen 
metabolites and breast density. Working in northern Greece and studying participants in a 
mammography screening program, Riza et al. measured urinary 2-OH and 16α-OH in 70 post-
menopausal women with dense (Wolfe P2 or DY parenchymal pattern) breasts and 70 post-
menopausal women with non-dense (Wolfe N1 parenchymal pattern) breasts, individually 
matched according to year of birth, years since menopause, and date of urine collection. Relative 
to the women with non-dense breasts, women with dense breasts had 58% higher levels of 2-OH, 
15% higher levels of 16α-OH, and a 35% higher 2-OH:16α-OH ratio. Relative to women in 
lowest tertile of the distribution for the 2-OH:16α-OH ratio, women in the highest tertile were 
much more likely to have dense (Wolfe P2/DY) as opposed to non-dense (Wolfe N1) breasts 
(odds ratio adjusted for potential confounders(age at first birth, current BMI, self-reported 
increase in body build from age 18), 6.2; 95% confidence interval (CI), 1.7-22.9). Notably, high, 
not the expected low ratio of 2-OH to 16α-OH associated with increased in breast density. 
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 Taking special note of the results reported by Riza et al., we sought to characterize the 
relationship between breast density and serum estrogen metabolite concentrations in pre- and 
post-menopausal western Pennsylvania women diagnosed free of breast cancer after screening 
mammography or after biopsy of a breast abnormality. 
 
3.3 Materials and Methods 
3.3.1 Study Population 
Subjects eligible for study included pre- or post-menopausal women with 1) no personal history 
of cancer (except skin) and 2) no evidence for breast cancer after mammography screening or 
breast biopsy. Volunteers arose from two sources: 1) women undergoing outpatient needle breast 
biopsy through the Breast Biopsy Service at Magee-Womens Hospital (Pittsburgh, Pennsylvania) 
and 2) women receiving screening mammography through Magee-Womens Hospital or through 
a suburban Pittsburgh Magee Womancare Center. To identify and recruit eligible subjects, a 
research assistant personally solicited women visiting the Breast Biopsy Service between 
September 2001 and May 2004 and women visiting either the Magee-Womencare Center – 
North (Wexford, Pennsylvania) or Magee-Womancare Center – East (Monroeville, 
Pennsylvania) between July 2002 and September 2003. To boost subject recruitment, Magee-
Womens Hospital attached study flyers to screening result reports mailed to Magee Womancare 
Center patrons with negative mammography (Breast Imaging Reporting And Data  (BIRAD) 
result levels 1 and 2) between November 2003 and May 2004. 
Of approximately 750 Breast Biopsy Service patients approached, 525 (70.0% of 750) women 
lacked a personal cancer history, agreed to participate, completed a personal interview, and 
produced a blood sample. A subsequent review of breast biopsy pathology reports verified non-
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 breast cancer outcomes in 313 (59.6% of 525) women, including 192 (61.3% of 313) women 
with serum estrogen metabolite and breast density results available. Of approximately 100 
Magee-Womancare Center – North and East patrons approached directly, 78 (78.0% of 100) 
women lacked a personal cancer history, agreed to participate, completed a personal interview, 
and produced a blood sample. Subsequent follow-up verified non-breast cancer outcomes in 77 
(98.7% of 78) women, including 71 (92.2% of 77) women with serum estrogen metabolite and 
breast density results available. Finally, mailing study fliers to 6482 women produced 240 (3.7% 
of 6482) responses, including 228 (95.0% of 240) responses from women without a personal 
cancer history. One hundred thirty (130; 57.0% of 228) women signed a written consent form, 
completed a study visit with personal interview, and produced a blood sample. After excluding 
one woman found to have breast cancer after additional follow-up, 117 (90.7% of 129) women 
had serum estrogen metabolite and breast density results available. Therefore, the final study 
sample included 380 women, including 192 (50.5%), 71 (18.7%), and 117 (30.8%) women 
recruited from the Breast Biopsy Service, Magee-Womancare Center – North or East, and mass 
mailings, respectively. 
Every subject included in this study signed a written informed consent document approved by 
the Magee-Womens Hospital Institutional Review Board. 
 
3.4 Data Collection 
Information collected at personal interview and recorded on standardized study forms included 
age, race, menopausal status (with menopause defined as 12 months since last menses), history 
of treatment with estrogen or progesterone, weight without shoes or heavy clothing (measured, in 
kilograms, with a standard balance beam scale), and height without shoes at full inspiration 
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 (measured, in centimeters, with a stadiometer). Other items of information collected through 
standardized self-administered take-home questionnaire included reproductive history (age at 
menarche, age of first pregnancy lasting at least six months, and number of births), details of 
menopause (including age at menopause and method (surgical vs. natural)), and family cancer 
history. After editing questionnaires for completeness and consistency, a research assistant 
telephoned subjects, when necessary, to retrieve missing information and to resolve 
inconsistencies. When subjects could not be reached, a research assistant attempted to retrieve 
missing information through review of written medical records. 
3.4.1 Breast Density 
From copies of the most recent screen-film mammogram obtained before the date of study entry, 
a consultant reader (Ms. Martine Salane), initially trained by Wolfe, used two methods to 
measure breast density. For women enrolled through the Breast Biopsy Service, we sent the 
mammogram for the breast not biopsied. For women enrolled following a negative screening 
mammogram, we selected the left or right breast mammogram in a manner designed to achieve 
balance with the mammograms sent for a concurrent case series of women with breast cancer 
(subject matter for a separate manuscript). First, visually inspecting the mammogram copies, the 
reader placed each subject into one of the four Wolfe parenchymal pattern categories. The N1 
Wolfe category included women with radiolucent (fatty) breasts containing few ducts; the P1 
Wolfe category included women with breasts showing a ductal (linear) pattern occupying less 
than 25% of the breast area; the P2 Wolfe category included women with breasts showing a 
ductal (linear) pattern and nodular densities occupying more than 25% of the breast area; and the 
DY Wolfe category included women with breast radio-density that completely obscured the 
ductal pattern. 
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 The second breast density method used the mammogram image showing the craniocaudal 
projection. Excluding biopsy scars, Cooper’s ligaments, and breast masses, the reader used a wax 
pencil and transparent overlay to outline the entire breast and the portions of breast containing 
radio-densities. Using a compensating polar planimeter (LASICO, Los Angeles, CA), the reader 
traced the outline of the entire breast and outlines of dense breast to compute total breast area 
and dense breast area, respectively. The calculated measure of breast density was the area of 
visibly dense breast, expressed as a percentage of the total breast. In 28 randomly selected 
mammograms re-sent blindly at a later date for a second breast density determination, the 
intraclass correlation coefficients for intra-observer agreement were 0.86, 0.99, and 0.89 for 
dense breast area, total breast area, and breast density percent, respectively. 
3.4.2 Laboratory Measurements 
We used the laboratory of TL Klug and enzyme immunoassays (ESTRAMETTM 2/16 ELISA, 
Immuna Care Corporation, Bethlehem, PA) to measure 2-OH and 16α-OH concentrations in 
serum stored at -70°C and subjected to a single freeze-thaw cycle. The ESTRAMET 2/16 ELISA 
assay has been validated against gas chromatography/mass spectroscopy in pooled serum spiked 
with known amounts of 2-OH and 16α-OH. The analytic sensitivities of the 2-OH and 16α-OH 
immunoassays are 20 pg/mL and 10 pg/mL, respectively. Using control sera with known 2-OH 
and 16α-OH concentrations, the laboratory reported concurrent within-assay coefficients of 
variation of 17% and 9% for 2-OH and 16α-OH concentration, respectively. The inter-assay 
coefficients of variation calculated from the analytic results reported for blinded duplicate serum 
samples from 25 postmenopausal subjects were 13.9% and 4.0% for 2-OH and 16α-OH 
concentration, respectively. 
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 3.5 Statistical Analysis 
To examine the association between breast density percent and questionnaire-based risk factors, 
we tabulated mean breast density percent according to risk factor level and used ANOVA (SAS 
PROC GLM) and Kruskal-Wallis tests (SAS PROC NPAR1WAY) to evaluate the statistical 
significance of group differences. To examine the association between serum estrogen metabolite 
concentrations and questionnaire-based risk factors, we tabulated geometric mean breast density 
percent according to risk factor level. To approximate the confidence interval for a geometric 
mean serum estrogen metabolite measure in a population subgroup, we exponentiated the 95% 
confidence interval calculated for the corresponding mean logarithm-transformed serum estrogen 
metabolite measure. We used analysis of variance (SAS PROC GLM) to evaluate the statistical 
significance of variations in a mean log-transformed estrogen metabolite measure across risk 
factor categories. 
For study subjects as a whole and for subjects sub-grouped according to menopausal status 
and current use of post-menopausal hormone therapy, we used Pearson correlations to express 
associations between the percent breast density measure and the estrogen metabolite measures 
(the logarithm-transformed 2-OH concentration, the logarithm-transformed 16α-OH 
concentration, and the logarithm-transformed ratio between the 2-OH concentration and the 16α-
OH concentration). We used Pearson partial correlation to evaluate breast density - estrogen 
metabolite associations adjusted for body mass index (BMI – weight in kg divided by the square 
of height in meters) and menopause-specific age quartile. We used menopause-specific age 
quartile to adjust for age in order to separate the effects of age and menopause. Finally, we used 
linear regression to estimate the apparent effects of 2-OH and 16α-OH (singly and together) on 
breast density percent, adjusted for menopausal status, current post-menopausal hormone 
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 therapy, menopause-specific age quartile, body mass index (BMI)), and questionnaire-based risk 
factors with meaningful univariate associations with breast density percent or estrogen 
metabolites (i.e., age at menarche and nulligravidity). We used the R-squared statistic and 
normal plots of residuals to evaluate the fit of linear regression models and linear regression after 
BoxCox transformation of the dependent variable to investigate the influence of minor 
departures of the breast density percent distribution from normality. 
Statistical analysis was performed with the SAS System for Windows, Release 8.02. 
 
3.6 Results 
 3.6.1   Characteristics of the study group 
The study group included 124 pre-menopausal women (median age 46 years, range 39-55 years; 
115 white, 6 other, and 3 unknown race; 34% overweight (BMI 25.0-29.9 kg/m2) and 24% obese 
(BMI 30.0+ kg/m2); 4 N1, 19 P1, 96 P2, and 5 DY Wolfe parenchymal pattern; median breast 
density 41%, inter-quartile range (IQR) 26-56%) and 256 post-menopausal women (median age 
59 years, range 44-84 years; 241 white, 11 other, and 4 unknown race; 37% overweight and 31% 
obese; 15 N1, 66 P1, 173 P2, and 2 DY Wolfe parenchymal pattern; median breast density 32%, 
IQR 16-49%). Forty-six (18%) and 210 (82%) post-menopausal women had experienced surgical 
and natural menopause, respectively. Among 251 post-menopausal women with known history 
of estrogen or progesterone hormone therapy (HT), 92 (37%) reported current use. 
3.6.2 Breast density percent measure 
As expected, breast density percent was higher in pre-menopausal (N=124, median 41%, IQR 
26-56%) than in post-menopausal women (N=256, median 32%, IQR 16-49%; p < 0.001 
Kruskal-Wallis). As well, breast density percent was higher in post-menopausal women taking 
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 hormones (N=92, median 37%, IQR 25-51%) than in post-menopausal women not taking 
hormones (N=159, median 27%, IQR 13-46%; p = 0.0105 Kruskal-Wallis). The distribution of 
breast density percent did not differ statistically between pre-menopausal women and post-
menopausal women taking hormones (p = 0.16 Kruskal-Wallis). Figure 1 shows the distribution 
of the breast density percent measure in pre-menopausal women and in post-menopausal women 
taking and not taking hormones. The distribution of breast density percent values, particularly for 
post-menopausal women not taking hormones, shows some departure from normality, with 
observations crowding together toward lower breast densities and a surplus of observations with 
zero values. Because of these distributional properties, the breast density percent measure is not 
perfectly suited for linear regression analysis. 
In subgroups defined according to menopausal status and hormone therapy, we looked for 
associations between breast density percent and other breast cancer risk factors, including age, 
race, BMI, family history of cancer, age at menarche, pregnancy history (never pregnant vs. any 
pregnancy lasting at least six months), age at first pregnancy lasting at least six months, number 
of births that followed pregnancies lasting at least six months, menopausal type (surgical vs. 
natural), and age at menopause. The limited number of non-white subjects in our study sample 
severely limited our ability to explore breast density differences according to race. Also, because 
detailed questions about menopause were added to study questionnaires midway through the 
subject recruitment period, information regarding age at menopause was available for only 127 
of 256 post-menopausal subjects. 
We observed, in each of the main study subgroups, the expected strong inverse association 
between BMI and breast density (Table 1). Breast density decreased with age (in three 
categories, 45-54, 55-64, and 65+ years) in post-menopausal women not taking HT (Table 1). 
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 This observation approached statistical significance (p=0.058) in an ANOVA model that 
included BMI (in three categories, <25.0, 25.0-29.9, and 30.0+ kg/m2) and age as an ordinal 
three-level variable (scored 0, 1, and 2 for the three categories of age, 45-54, 55-64, and 65+ 
years, respectively). 
In addition, pre-menopausal subjects with menarche at age 13 years or later (N=53) had 
denser breasts than pre-menopausal subjects with earlier menarche (N=68; mean breast density 
47.6% vs. 35.7%, p<0.01; Table 1). Adjustments for age (in three categories, <45, 45-49, and 
50+ years) and BMI (in three categories, <25.0, 25.0-29.9, and 30.0+ kg/m2) reduced the breast 
density difference between pre-menopausal women with late vs. early menarche (mean breast 
density 44.9% vs. 37.8%, p<0.05). The difference remained statistically significant (p<0.05) 
after BoxCox transformation (with λ=0.75) of the breast density percent dependent variable. 
Finally, nulligravid post-menopausal women not on HT (N=24) had denser breasts than post-
menopausal women not on HT with at least one pregnancy lasting six months (N=129; 45.6% vs. 
27.9%, p<0.001; Table 1). Again, adjustments for age (in three categories, <55, 55-64, and 65+ 
years) and BMI (in three categories, <25.0, 25.0-29.9, and 30.0+ kg/m2) reduced this post-
menopausal breast density difference according to pregnancy history (mean breast density 41.3% 
vs. 28.7%, p<0.01). Statistical significance remained after the BoxCox transformation. 
3.6.3  Serum estrogen metabolite measures 
Menopausal status and hormone therapy were clearly related to the serum concentrations of the 
estrogen metabolites. Relative to pre-menopausal women (N=124, median 422 pg/ml, IQR 374-
480 pg/ml) and post-menopausal women on HT (N=92, median 412 pg/ml, IQR 356-524 pg/ml), 
post-menopausal women not on HT had low serum concentrations of 16α-OH (N=159, median 
351 pg/ml, IQR 316-426 pg/ml; Figure 2, Panel A). Post-menopausal women on HT (median 
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 348 pg/ml, IQR 194-472 pg/ml), pre-menopausal women (median 251, IQR 163-388 pg/ml), and 
post-menopausal women not on HT (median 158 pg/ml, IQR 117-218 pg/ml) had high, 
intermediate, and low serum concentrations of 2-OH (Figure 2, Panel B). In accordance with 
these differences with respect to 2-OH , post-menopausal women on HT (median 0.74, IQR 
0.47-1.10 pg/ml), pre-menopausal women (median 0.53, IQR 0.40-0.83), and post-menopausal 
women not on HT (median 0.43, IQR 0.31-0.59) had high, intermediate, and low values for the 
ratio of 2-OH concentration to 16α-OH concentration (Figure 2, Panel C). For each of the three 
estrogen metabolite measures, the differences between post-menopausal women on and not on 
HT and the differences between pre-menopausal women and post-menopausal women not on HT 
were statistically significant (p<0.0001, Kruskal-Wallis). As well, pre-menopausal women and 
post-menopausal women on HT differed significantly with respect to 2-OH concentration and 
with respect to the 2-OH: 16α-OH metabolite ratio (p<0.01, Kruskal-Wallis). Pre-menopausal 
women and post-menopausal women on HT were not statistically different with respect to the 
16α-OH metabolite measure. 
Again, in subgroups defined according to menopausal status and hormone therapy, we 
looked for associations involving the serum estrogen metabolite measures and traditional breast 
cancer risk factors. Table 2 summarizes findings for age, BMI, age at menarche, and pregnancy 
history (never pregnant vs. any pregnancy lasting at least six months). The estrogen metabolite 
measures were unrelated to age. Among post-menopausal women on HT, increases in BMI 
tracked with decreases in 2-OH and with decreases in the ratio of 2-OH to 16α-OH. As a result, 
the previously noted higher 2-OH estrogen concentrations and estrogen metabolite ratios 
observed among post-menopausal hormone users relative to non-users were magnified among 
women with lower BMI. There was statistical evidence for significant variation in geometric 
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 mean 16α-OH concentrations across BMI categories among pre-menopausal women and among 
post-menopausal women not on HT (Table 2). Within these two subgroups, obese women (BMI 
≥ 30 kg/m2) relative to normal BMI women (BMI < 25 kg/m2) had a lower geometric mean 2-
OH concentration, a higher geometric mean 16α-OH concentration, and lower geometric mean 
ratio of 2-OH concentration to 16α-OH concentration. In pre-menopausal women, the geometric 
mean 2-OH:16α-OH metabolite ratio was higher among women with earlier menarche than 
among women with later menarche. Finally, in pre-menopausal women, the geometric mean 
16α-OH estrogen concentration was higher among women without prior pregnancy than among 
women with any prior pregnancy lasting at least six months. These latter two observations were 
not quite statistically significant. 
3.6.4  Crude and adjusted associations between breast density and the individual   
  estrogen metabolite measures (Figures 3 and 4) 
 
In all subjects, breast density correlated weakly with log-transformed serum concentrations of 
16α-OH (Pearson correlation coefficient (ρ) = 0.10, p-value < 0.1; Figure 3, Panel A, Plot A) and 
with log-transformed serum concentrations of 2-OH (ρ = 0.13, p-value < 0.05; Figure 3, Panel B, 
Plot A). Adjustments for BMI and menopause-specific age quartile increased the breast density 
correlation for 16α-OH (Pearson partial correlation coefficient (partial ρ) = 0.13, p-value < 0.05; 
Figure 4, Panel A, Plot A) and decreased the breast density correlation for 2-OH (partial ρ = 
0.09, p-value < 0.1; Figure 4, Panel B, Plot A). Excluding post-menopausal subjects who were 
taking hormone medications or who were missing information about hormone medications did 
not materially alter the strength of association between breast density and 16α-OH (partial ρ = 
0.12; p-value < 0.1; Figure 4, Panel A, Plot B) or between breast density and 2-OH (partial ρ = 
0.09; p-value = not significant; Figure 4, Panel B, Plot B). Further stratification according to 
menopausal status (Figure 4, Panels A and B, Plots C and D) reduced or eliminated associations 
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 between breast density and the estrogen metabolites. A weakened adjusted association between 
breast density and 16α-OH persisted among post-menopausal women not on hormone therapy 
(partial ρ = 0.07; p-value = not significant; Figure 4, Panel B, Plot D). A statistically non-
significant adjusted association between breast density and 16α-OH was observed among the 
small number of post-menopausal women on hormone therapy (partial ρ = 0.07; p-value = not 
significant; Figure 4, Panel A, Plot E). The effective absence of BMI- and menopause-specific 
age quartile-adjusted associations between breast density and the estrogen metabolite ratio 
(Figure 4, Panel C) was consistent with the generally positive weak associations between breast 
density and the individual estrogen metabolites (Figure 4, Panels A and B). 
3.6.5 Crude and adjusted associations between breast density and the 2-OH and 
16α-OH measures, taken together (Table 3) 
 
Table 3 summarizes the mutual effects of the estrogen metabolites on breast density. Table 3 
expresses estrogen metabolite-breast density associations in terms of standardized beta 
coefficients, the estimated increase in breast density per standard deviation unit increase in log-
transformed estrogen metabolite concentration (Table 3, footnote). Germane to the sub-group not 
taking post-menopausal hormones, both 16α-OH (BMI- and menopause-specific age quartile-
adjusted standardized beta = 1.9, standard error (S.E.) = 1.3) and 2-OH (adjusted standardized 
beta = 1.1, S.E. = 1.3) contributed positively and independently to breast density. Upon further 
stratification according to menopausal status, some evidence emerged, at least in post-
menopausal women not on hormone therapy, for opposing effects of 16α-OH (adjusted 
standardized beta = 1.7, S.E. = 1.6) and 2-OH (adjusted standardized beta = −0.7, S.E. = 1.9) on 
breast density. A similar pattern was observed in post-menopausal women on hormone therapy 
(adjusted standardized beta for 16α-OH = 2.6, S.E. = 2.0) and adjusted standardized beta for 2-
OH = −1.1, S.E. = 2.1). 
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 3.6.6 Final linear regression mode (Table 4) 
Table 4 summarizes results from a single and simple linear regression breast density model 
(R2=0.308) with menopausal status, current hormone therapy use, BMI, menopause-specific age 
quartile, 16α-OH and 2-OH included as main effects. Results from the model underscored the 
independent and statistically significant effects of BMI, menopause, and hormone therapy on 
breast density. The model ascribed a statistically non-significant 1.3 percentage point increase 
(S.E. = 1.1) in breast density percent with each one standard deviation unit increase in the 
logarithm of the serum concentration of 16α-OH. The model recognized no association between 
2-OH and breast density percent (beta = −0.1, S.E. 1.1; Table 4). The residuals appeared 
normally distributed. 
A more complete (main effect) model (R2 = 0.327) added two factors (age at menarche and 
pregnancy history) connected earlier with breast density (Table 1). According to the model, 
pregnancy history (pregnant at least 6 months vs. never pregnant) decreased breast density 
percent 7.8 percentage points (S.E. = 2.5, p-value < 0.01) and late menarche (13+ years vs. <13 
years) increased breast density 1.5 percentage points (S.E. = 1.9, p-value = not significant). 
Because of exclusions for history of pregnancies only lasting less than six months (N=11), for 
missing age at menarche (N=1), and for missing age at menarche and missing pregnancy history 
(N=5), this latter model included data from 357 instead of 374 women. 
 
3.7 Discussion 
Breast density and estrogen metabolism have both been implicated in the risk of developing 
breast cancer.  Our main aim was to identify the relationship between breast density and serum 
estrogen metabolite concentrations in pre- and post-menopausal women without breast cancer. 
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 In our overall sample, estrogen metabolites were positively correlated with breast density.  
These associations appeared independent of post-menopausal hormone medication use. 
However, statistical associations disappeared upon control for menopausal status.  To our 
knowledge, the only other study to evaluate the relationship between estrogen metabolites and 
breast density is Riza et al(45).  However, the sample was restricted to postmenopausal women 
not on HT, thereby limiting our ability to compare our results between estrogen metabolites and 
breast density with results reported by Riza.  To our knowledge this is the first study to look at 
estrogen metabolites and correlates of breast density.   
Mammographic breast density serves as an estimate of the proportion of fibroglandular 
tissue to fat in the breast.  Premenopausal women, compared to postmenopausal women, 
generally have greater breast density secondary to a higher proportion of glandular tissue.  As 
women age, fatty tissue replaces glandular tissue therefore decreasing breast density(12, 25, 29, 
35).  Consistent with this theory, reports in the literature illustrate a decrease in mammographic 
breast density with age, especially after the menopause(27). 
In concert with the literature, we found that the mean percent breast density was higher in 
premenopausal women than postmenopausal women not taking HT.  Furthermore, consistent 
with reports that have shown HT, in particular combination therapy, increases breast density(8), 
we also noted higher mean percent density in postmenopausal women on HT.   
Consistent with the literature, we found that BMI was inversely related to breast density 
percent in all subgroups.  Several studies have shown an inverse relationship between weight and 
BMI and mammographic density(7, 13, 15, 25, 30, 51).  In reports,  increased leanness equates 
with increased breast density and increased risk of breast cancer in premenopausal women and in 
postmenopausal women an inverse relationship exists between obesity and mammographic 
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 density.  This is suggestive that in postmenopausal women the increased risk of breast cancer in 
heavier women which has been associated with increased levels of estrogen (5, 7, 16, 38, 47), 
may not be mediated through density.  In one study by Coker et al (20), African-American 
women had significantly lower 2-OH levels than Caucasian women among pre-and 
postmenopausal women and was felt to be related to ethnic differences in body mass.  While we 
were not able to evaluate differences in BMI with respect to estrogen metabolism across ethnic 
groups, we did note in leaner women (BMI <25 kg/m2) higher 2-OH levels in pre-and 
postmenopausal women on HT compared to heavier women.  Additionally, leaner 
postmenopausal women on HT had higher 16α-OH levels.   
Nulliparity is related to denser breast tissue and subsequently increased breast cancer risk(7, 
22, 51, 52).  Pregnancy is associated with a change in breast structure to more differentiated 
lobules with less cell proliferation with the greatest effect on breast structure obtained from the 
first pregnancy, and further differentiation with each subsequent pregnancy(46).  Our results 
revealed greater percent breast density in nulligravid postmenopausal women not on HT than 
postmenopausal women not on HT with at least one pregnancy.  This association remained 
statistically significant even with adjustment for age indicating that age and pregnancy 
independently influence breast cancer risk.  With respect to the estrogen metabolites, mean 16α-
OH concentrations were higher in nulligravid premenopausal women, although not statistically 
significant.    
 Menarche occurring 13 years and older yielded significantly denser breast tissue when 
compared with women who began menstruating at <13 years, particularly in the premenopausal 
population.  This is in contrast to what we would expect as early age at menarche has been 
associated with an increased risk of breast cancer as well as increased mammographic density 
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 suggesting the association with ovarian function(7, 17).  Again, in premenopausal women, only 
the mean 2-OH:16α-OH ratio was associated with an earlier age at menarche vs. later menarche, 
although not statistically significant.  Adjustment for age at menarche did not substantially 
impact our findings with respect to apparent effects of metabolites and density.  
There are several features of the present study that warrant discussion.  To our knowledge, 
this is the first study to examine breast density, serum estrogen metabolites, and breast cancer 
risk factors in pre-and postmenopausal women.  The use of a single, expert breast density reader 
helps to reduce variability in breast density measurements.  Estrogen metabolite levels in 
premenopausal women may be subject to fluctuations in the menstrual cycle.  As we were unable 
to determine the phase at time of blood draw, variability may exist among pre-menopausal 
women with respect to the estrogen metabolite measures and the respective breast density 
measurement.  Lastly, the use of serum vs. urine to measure estrogen metabolites may make it 
difficult to compare to previous studies which have predominantly used urine for metabolite 
measures.  In a study by Bradlow et al(10), plasma and urinary levels of 2OH and 16α-OH were 
compared in nulliparous women aged 17-35 years.  Overall, the correlation between the two 
methods was felt to be fair.  While the comparison was only conducted in premenopausal women 
it is suspected that the amount of variation would be less in the postmenopausal population.  The 
low number of HT users does not allow us to address the differences associated with HT 
preparations.   Reproductive and lifestyle factors were obtained by self-report which may lend to 
recall bias, thereby attenuating our results.  Finally, we cannot exclude the possibility that our 
findings may be due to chance or confounded by some unidentified factor.   
In conclusion, this is the first study to investigate estrogen metabolites and correlates of 
breast density in pre-and postmenopausal women.  The associations between the estrogen 
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 metabolites and breast density appeared independent of post-menopausal hormone medication 
use. However, statistical associations disappeared upon control for menopausal status.  Our 
findings suggest that serum estrogen metabolite concentrations and breast density may share 
common determinants that are related to the menopause. Or, estrogen metabolite changes, 
occurring as a consequence of menopause, may directly contribute to the menopause-associated 
declines in breast density. Determination of the menopause-specific cross-sectional associations 
between the serum estrogen metabolites and breast density may require larger studies, with 
sufficient numbers of pre- and post-menopausal women. 
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Figure 3-1 Combination dot-box plots of breast density percent 
Combination dot-box plots of breast density percent in pre-menopausal subjects and in 
post-menopausal subjects not taking and taking hormone therapy (HT). The lower and 
upper boundaries of each box indicate the 25th and 75th percentiles, respectively. The line 
through the mid-portion of each box indicates the median. 
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Figure 3-2: Combination dot-box plots of the log-transformed serum concentrations of 16α-
OH 
Combination dot-box plots of the log-transformed serum concentrations of 16α-OH (Panel 
A), of the log-transformed serum concentrations of 2-OH (Panel B), and the log-
transformed ratios of 2-OH concentration to 16α-OH concentration (Panel C). Each panel 
contains a dot-box plot for pre-menopausal subjects, post-menopausal subjects not on HT, 
and post-menopausal subjects on HT. The lower and upper boundaries of each box 
indicate the 25th and 75th percentiles, respectively. The line through the mid-portion of each 
box indicates the median. The whiskers extend to the upper fence (75th percentile + 1.5 · 
IQR) and to the lower fence (25th percentile - 1.5 · IQR). 
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Figure 3-2 (Cont’d) 
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Figure 3-2 (Continued) 
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 Figure 3-3 Description 
 
Scatter plots of the log-transformed serum concentrations of 16α-OH (Panel A), of the log-transformed serum concentrations of 2-OH 
(Panel B), and the log-transformed ratios of 2-OH concentration to 16α-OH concentration (Panel C), in subgroups defined according 
to menopausal status and HT use. Each panel includes a table of correlations of log-transformed metabolite measure with breast 
density percent. Each scatter plot shows the least square regression line of breast density percent fit to the log-transformed metabolite 
measure. (Note: HT use is missing for five post-menopausal subjects.) Abbreviations: * − p-value <0.1, ** − p-value <0.05 
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 Pearson correlations with breast density 
percent 
N
A. All subjects 380 0.10 **
B. Pre-menopausal and post-
menopausal, no HT
283 0.11 *
C. Pre-menopausal 124 0.09
D. Post-menopausal, no HT 159 0.03
E. Post-menopausal, HT 92 0.08
CorrelationGroup
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Figure 3-3-A:  Scatter plots of 16α-OH 
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 Pearson correlations with breast density 
percent 
N
A. All subjects 380 0.13 **
B. Pre-menopausal and post-
menopausal, no HT
283 0.12 **
C. Pre-menopausal 124 0.06
D. Post-menopausal, no HT 159 0.02
E. Post-menopausal, HT 92 0.14
CorrelationGroup
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Figure3-3-B:  Scatter plots of 2-OH
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Figure 3-3-C:  Scatter plots of 2:16α-OH 
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 Figure 3-4 description 
 
Scatter plots of the log-transformed serum concentrations of 16α-OH (Panel A), of the log-transformed serum concentrations of 2-OH 
(Panel B), and the log-transformed ratios of 2-OH concentration to 16α-OH estrogen concentration (Panel C), in subgroups defined 
according to menopausal status and HT use. Breast density percent and each of the log-transformed metabolite measures have been 
adjusted for log-transformed BMI and menopause-specific age quartile (treated as an integer-scored ordinal variable). Adjusted breast 
density percent values were set equal to zero when linear regression results produced adjusted values less than zero. This correction 
affected one pre-menopausal subject with adjusted density calculated at -2.0%, four no HT post-menopausal subjects with adjusted 
densities calculated at -11.4, -3.1, -0.9, and -2.6%, and one HT post-menopausal subject with adjusted density calculated at -0.8%.Age 
quartile categories are <43, 43-45, 46-48, and 49+ years and <55, 55-59, 60-63, and 64+ years for pre- and post-menopausal subjects, 
respectively. Each panel includes a table of correlations of the BMI- and age-adjusted log-transformed metabolite measure with BMI- 
and age-adjusted breast density percent. Each scatter plot shows the least square regression line of BMI- and age-adjusted breast 
density percent fit to the BMI- and age-adjusted log-transformed metabolite measure. (Note: HT use is missing for five post-
menopausal subjects and BMI for one post-menopausal subject on HT.) Abbreviations: * value <0.1, ** − p-value <0.05 
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 A Partial correlations with breast density 
percent 
N
A. All subjects 379 0.13 **
B. Pre-menopausal and post-
menopausal, no HT
283 0.12 *
C. Pre-menopausal 124 0.00
D. Post-menopausal, no HT 159 0.07
E. Post-menopausal, HT 91 0.11
Group Correlation
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Figure 3-4-A: Scatter plots of 16α-OH
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A. All subjects 379 0.09 *
B. Pre-menopausal and post-
menopausal, no HT
283 0.09
C. Pre-menopausal 124 0.04
D. Post-menopausal, no HT 159 -0.01
E. Post-menopausal, HT 91 0.03
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Figure 3-4-B:  Scatter plots of 2-OH
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  Figure 3-4-C:  Scatter plots of 2:16α-OH 
Partial correlations with breast density 
percent 
N
A. All subjects 379 0.04
B. Pre-menopausal and post-
menopausal, no HT
283 0.05
C. Pre-menopausal 124 0.04
D. Post-menopausal, no HT 159 -0.04
E. Post-menopausal, HT 91 -0.02
Group Correlation
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 Table 3-1: Mean breast density percent according to breast cancer risk factor level  
 Pre-menopausal (N=124) Post-menopausal, no HT (N=159) Post-menopausal, HT (N=92) 
Risk factor N Mean 95%C.I. p-value N Mean 95% C.I. p-value N Mean 95% C.I. p-value 
Age (years)   N.S.   N.S.  N.S. 
<45 50 41.6 35.6-47.6       
45-54 73 41.4 36.6-46.2   33 34.6 26.1-43.2   27 36.1 28.3-43.9  
55-64     84 31.5 27.0-36.0   51 36.0 30.5-41.5  
65+     42 26.1 20.4-31.8   13 41.0 29.2-52.7  
Age tertile   N.S.   N.S.  N.S. 
low 39 42.5 35.7-49.4   55 34.8 28.9-40.7   35 36.1 29.0-43.2  
middle 43 39.0 32.9-45.0   53 30.9 24.8-36.9   29 35.3 29.6-41.0  
upper 42 42.3 35.6-49.1   51 26.2 21.0-31.5   28 39.0 30.4-47.6  
BMI (kg/m2)   <0.0001   <0.0001  <0.0001
<25 52 52.6 47.0-58.1   54 42.3 36.2-48.4   26 47.2 40.7-53.7  
25-29 42 36.8 31.2-42.5   53 32.6 27.9-37.2   41 37.2 31.5-43.0  
30+ 30 27.7 22.1-33.3   52 16.8 12.7-21.0   24 24.8 16.9-32.6  
Menarche (years)   <0.01   N.S.  N.S. 
<13 68 35.7 31.3-40.0   72 30.4 25.1-35.8   39 33.2 27.0-39.3  
13+ 53 47.6 41.8-53.4   86 31.0 26.8-35.3   52 38.9 33.5-44.3  
Pregnancy history   N.S.   <0.0001  N.S. 
never 19 45.2 33.4-57.0   24 45.6 36.4-54.9   14 37.9 24.9-50.9  
ever 99 39.9 36.0-43.8   129 27.9 24.4-31.4   73 35.9 31.6-40.3  
Abbreviations: HT – hormone therapy; C.I. – confidence interval; N.S. – not significant; BMI – body mass index 
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 Notes: 
1. Statistical significance of differences in mean breast density percent across risk factor category based on Kruskal-Wallis test 
(performed with SAS PROC NPAR1WAY). 
2. Analysis according to age excludes one 55-59 year-old pre-menopausal subject and one <45 year-old post-menopausal 
subject on HT. 
3. Low, middle, and upper age tertiles include <44, 44-47, and 48+ year-old women, if pre-menopausal, <57, 57-62, and 63+ 
year-old women, if post-menopausal not on HT, or <56, 56-60, and 61+ year-old women, if post-menopausal on HT. 
4. BMI is unknown for one post-menopausal subject on HT. 
5. Age at menarche is unknown for five subjects (three pre-menopausal, one post-menopausal not on HT, and one post-
menopausal on HT). 
6. Analysis according to pregnancy history excludes eleven subjects with pregnancies not lasting six months (three pre-
menopausal, five post-menopausal not on HT, and three post-menopausal on HT). In addition, pregnancy history is 
unknown for six subjects (three pre-menopausal, one post-menopausal not on HT, and two post-menopausal on HT). 
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 Table 3-2: Geometric mean serum 2-OH, 16α-OH and metabolite ratio according to breast cancer risk factor level 
 Pre-menopausal (N=124)  Post-menopausal, no HT (N=159)  Post-menopausal, HT (N=92) 
Risk factor N 2-OH 16α-OH Ratio  N 2-OH 16α-OH Ratio  N 2-OH 16α-OH Ratio 
Age (years)               
<45 50 236 
201-277 
441 
415-469 
0.53 
0.46-0.62 
         
45-54 73 248 
213-288 
425 
403-447 
0.58 
0.51-0.67 
 33 172 
141-209 
363 
326-405 
0.47 
0.38-0.58 
 27 283 
202-397 
482 
428-543 
0.59 
0.45-0.77 
55-64      84 160 
142-180 
371 
352-390 
0.43 
0.39-0.48 
 51 321 
263-392 
434 
395-476 
0.74 
0.62-0.88 
65+      42 156 
136-179 
361 
328-397 
0.43 
0.37-0.51 
 13 324 
248-423 
415 
356-485 
0.78 
0.61-1.00 
Age tertile               
low 39 242 
202-289 
436 
405-468 
0.55 
0.47-0.65 
 55 148 
127-172 
364 
339-391 
0.41 
0.35-0.48 
 35 288 
219-379 
469 
423-519 
0.61 
0.49-0.77 
middle 43 226 
188-273 
421 
396-448 
0.54 
0.45-0.64 
 53 174 
153-199 
377 
354-402 
0.46 
0.41-0.52 
 29 288 
218-380 
420 
381-463 
0.69 
0.54-0.88 
upper 42 262 
213-323 
440 0.60 
0.49-0.72 
 51 162 
141-188 
358 
328-391 
0.45 
0.39-0.52 
 28 359 
285-453 
440 
409-474 380-510 
0.82 
0.67-0.99 
BMI   **     **    ***  ** 
<25 52 268 
223-322 
431 
407-457 
0.62 
0.53-0.73 
 54 161 
140-186 
341 
316-367 
0.47 
0.41-0.55 
 26 413 
312-547 
471 
409-542 
0.88 
0.72-1.07 
25-29 42 221 
185-265 
410 
388-433 
0.54 
0.46-0.64 
 53 165 
145-189 
384 
355-416 
0.43 
0.37-0.50 
 41 313 
252-388 
445 
402-492 
0.70 
0.58-0.86 
30+ 30 232 
188-287 
467 0.50  52 157 377 0.42 
0.36-0.48 
 24 222 
165-299 
421 
421-517 0.40-0.61 134-183 353-402 377-470 
0.53 
0.41-0.68 
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Table 3-2 (Continued) 
 
 
 Pre-menopausal (N=124)  Post-menopausal, no HT (N=159)  Post-menopausal, HT (N=92) 
Risk factor N 2-OH 16α-OH Ratio  N 2-OH 16α-OH Ratio  N 2-OH 16α-OH Ratio 
Menarche    *           
<13 68 268 
232-309 
432 
408-457 
0.62 
0.54-0.71  
72 164 
144-187 
369 
351-389 
0.44 
0.39-0.50  
39 298 
246-361 
426 
394-460 
0.70 
0.59-0.84 
13+ 53 221 
187-262 
436 0.51 
0.44-0.59  
86 160 
144-177 
364 
341-388 
0.44 
0.39-0.49  
52 318 
254-398 
457 
412-462 414-506 
0.70 
0.58-0.84 
Pregnancy   *            
never 19 250 
179-349 
471 
422-525 
0.53 
0.39-0.72  
24 167 
126-220 
380 
329-438 
0.44 
0.33-0.59  
14 307 
206-456 
423 
367-488 
0.73 
0.52-1.00 
ever 99 247 
219-278 
427 0.58 
409-445 0.52-0.65  
129 160 363 
347-380 
0.44 
0.41-0.48  
73
147-175 
314 
264-373 
449 
416-485 
0.70 
0.60-0.81 
 
Abbreviations: HT – hormone therapy; 2-OH – serum 2-OH estrogen concentration (pg/ml); 16α-OH – serum 16α-OH estrogen 
concentration (pg/ml); ratio – ratio of 2-OH to 16α-OH; BMI – body mass index; * – p<0.1; ** – p<0.05; *** – p<0.01 
Notes: See Table 1 
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 Table 3-3: Multiple linear regression results 
Unadjusted and adjusted effects of serum 2-OH and serum 16α-OH metabolite measures, separately and together, on breast 
density percent, in subject groups defined according to menopausal status and HT. 
  Unadjusted  Age- and BMI-adjusted 
  2-OH  16α-OH    2-OH  16α-OH  
R2 R2Subject group Metabolite measure B SE  B SE   B SE  B SE 
  None    0.269All subjects 
(N=374) 
  
 ** 2-OH 2.6 1.1  0.016  1.6 0.9 0.278 * 
 **  16α-OH 1.7 1.1 0.006  2.2 0.9 0.284  
* *  2-OH and 16α-OH 2.4 1.2 0.5 1.3 0.016  0.7 1.1 1.9 1.1 0.284  
       None 0.290All subjects, ex-
cept HT (N=283) 2-OH 2.8 1.4 **   0.014  1.9 1.2   0.297
 16α-OH  1.1 1.4  0.002   2.4 1.2 ** 0.301
2-OH and 16α-OH 2.8 1.5 * 0.0 1.5  0.014  1.1 1.3  1.9 1.3   
 
 
 
0.302
None        0.313Pre-menopausal 
(N=124) 
 
2-OH 1.4 2.0    0.004  0.7 1.7   0.314
16α-OH  -1.8 2.4  0.005   -0.1 2.0  0.313
2-OH and 16α-OH 2.3 2.2  -2.8 2.6  0.013  0.8 1.9  -0.5 2.2  0.314
None        0.274Post-menopausal, 
no HT (N=159) 
 
2-OH 0.6 2.1    0.000  0.0 1.8   0.274
16α-OH  -0.2 1.8  0.000   1.5 1.5  0.278
2-OH and 16α-OH 0.7 2.2  -0.3 1.9  0.001  -0.7 1.9  1.7 1.6  0.279
None        0.221Post-menopausal, 
on HT (N=91) 
 
2-OH 2.4 1.9   0.018  0.4 1.7   0.221
16α-OH  2.7 1.9  0.023   2.0 1.7  0.234
  2.0 2.2  0.027  -1.1 2.1  2.6 2.02-OH and 16α-OH 1.3 2.2 0.236
Abbreviations: HT – hormone therapy; 2-OH – serum 2-OH estrogen; 16α-OH – serum 16α-OH estrogen; BMI – body mass index; B 
– beta coefficient; SE – standard error; * – p<0.1; ** – p<0.05 
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Notes: 
1. Adjusted linear regression models include terms for log-transformed BMI and menopause-specific age quartile (treated as 
an integer-scored ordinal variable). Age quartile categories are <43, 43-45, 46-48, and 49+ years and <55, 55-59, 60-63, and 
64+ years for pre- and post-menopausal subjects, respectively. 
2. Beta coefficients estimate the increase in breast density percent associated with a one standard deviation unit increase in the 
estrogen metabolite measure (i.e., 0.663 unit increase and 0.285 unit increase in natural logarithm serum 2-OH and 16α-OH 
estrogen concentration, respectively). 
 3. BMI is unknown for one post-menopausal subject on HT. HT status is unknown for five post-menopausal subjects. 
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 Table 3-4: Final linear regression model (N=374,R2=0.308) 
 Breast density percent increase in 
Model term association with beta SE p-value 
Intercept  182.3 24.6 <0.0001
BMI 0.212 unit increase in ln(BMI) -10.7 0.9 <0.0001
Menopause post-menopause vs. pre-
menopause 
-7.9 2.2 <0.001 
HT current post-menopausal HT 
use vs. non-use 
4.8 2.6 0.059 
Age one category increase in meno-
pause-specific age quartile 
-1.1 0.8 N.S. 
1.3 1.1 N.S. 16α-OH 0.285 unit increase in ln(16α-
OH concentration) 
2-OH 0.663 unit increase in ln(2-OH 
concentration) 
-0.1 1.1 N.S. 
 
Abbreviations: BMI – body mass index; HT – hormone therapy; 2-OH – serum 2-OH estrogen; 
16α-OH – serum 16α-OH estrogen; beta – beta coefficient; SE – standard error 
 
Notes: 
1. Age quartile categories are <43, 43-45, 46-48, and 49+ years and <55, 55-59, 60-63, 
and 64+ years for pre- and post-menopausal subjects, respectively. 
 2. Analysis excludes one subject because of unknown BMI and five subjects because of 
unknown HT status. 
3. The beta coefficients for BMI, 16α-OH, and 2-OH convey the breast density percent 
change per standard deviation change in natural logarithm BMI, natural logarithm 
16α-OH, and natural logarithm 2-OH, respectively. 
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 4.1    Abstract 
 
BACKGROUND:  Epidemiological evidence suggests that breast density and measures of 
estrogen metabolism (blood and urinary levels of 2-hydroxyestrone (2-OH) and 16alpha-
hydroxyestrone (16α-OH)) are associated with breast carcinogenesis. We sought to determine 
whether these factors are independently associated with breast cancer risk.   
METHODS: Percent breast density and serum concentrations of 2-OH and 16α-OH were 
obtained on 176 cases (55 pre-menopausal, 121 post-menopausal) and 380 controls (124 pre-
menopausal, 256 postmenopausal).   
RESULTS: Logistic regression analyses showed a 3-4 fold increased risk of breast cancer 
among pre-menopausal women in the highest tertile of breast density compared with those in the 
lowest tertile of density, even with adjustment for the estrogen metabolites.  A similar trend for 
increased risk of breast cancer in high vs. low tertile of density was observed among post-
menopausal women taking hormone therapy (HT) after adjusting for estrogen metabolites, BMI, 
and age, but this trend was not statistically significant.  Breast density did not appear to 
substantially increase breast cancer risk among post-menopausal women not taking HT.  
CONCLUSION:  A breast density-breast cancer risk relationship, that is independent of serum 
estrogen metabolite concentrations, exists in subgroups of women classified according to 
menopausal status and HT use.   
Key Words: Breast Density, Estrogen Metabolism, Breast Cancer 
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 4.2   Introduction 
Breast cancer remains the most common cancer in women with an estimated 211,240 new cases 
in the United States in 2005(1).  Mammographic breast density and estrogen metabolites, namely 
2-hydroxyestrone (2-OH) and 16α-hydroxyestrone (16α-OH) have been implicated as risk 
factors for this disease. 
Breast density is associated with an increased risk of breast cancer in both premenopausal 
and postmenopausal women (8, 10).  The extent to which this association is a measurable 
manifestation of a biological state or a process related to breast carcinogenesis remains unknown.  
It has been postulated that sex hormone-induced breast epithelial and stromal cell hyper-
proliferation(3-5, 7, 9, 12, 21, 50, 53), growth factor expression(11, 14, 24), and DNA 
damage(29) may be contributing to breast density.  As women age, fatty tissue replaces glandular 
tissue therefore decreasing breast density.  Breast density clearly increases in women placed on 
post-menopausal hormones(6, 17, 20, 32, 33, 35-37, 41, 42, 47), an exposure causally related to 
breast cancer(54).  Evidence exists that the tissue composition of dense and non-dense breasts 
differ.  Connective tissue, including collagen and fibroblasts, along with epithelial cells, 
predominate in dense breasts.  Several studies have evaluated the relationship between density as 
it appears radiologically with the histology of breast tissue.  Nine of ten studies used samples 
from a mastectomy or biopsy and six of these studies reported an association between density 
and epithelial proliferation and density and stromal proliferation(3-5, 7, 9, 12, 21, 50, 53).  A 
concern was that these samples might not be representative of the general population.  Li and 
colleagues reported on a study using samples from women at forensic biopsy which revealed a 
higher percentage of the tissue occupied by cells, glandular structures, and collagen in dense 
breasts(4, 10, 34).  
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 Outside of age and mutations in BRCA1 or BRCA2, density carries the largest risk for 
breast cancer with a four to six-fold increase in risk in those women with densest breast tissue(9, 
10).  What remains unclear is the best way to measure density. Breast density can be assessed 
either qualitatively or quantitatively.  The first qualitative method proposed by Wolfe in 1976, 
consists of four classifications: N1 radiolucent (fatty) breasts containing few ducts; P1 ductal 
(linear) pattern occupying less than 25% of the breast area; P2 ductal (linear) pattern and nodular 
densities occupying more than 25% of the breast area; and the DY radio-density that completely 
obscured the ductal pattern.  The breast imaging reporting and data systems (BIRADS) is another 
qualitative classification.  This system also utilizes four categories: extremely fatty; scattered 
density; heterogeneous density; and extremely dense.  Several studies have found the Wolfe 
categories to predict breast cancer risk, and although few studies have utilized the BIRADS 
classification, those reported show a significant increase risk in the extremely dense 
category(10).  Studies investigating the association between breast density and breast cancer 
using quantitative approaches have reported more consistent results and larger gradients of risk 
when compared to qualitative methods(10, 52).  Current quantitative methods include computer-
assisted methods, estimation by radiologists and planimetry.  Despite current methods of 
measuring breast density, a standard approach for measurement is lacking and methodological 
limitations are evident.  Both qualitative and quantitative methods have an element of 
subjectivity lending to the possibility of inter-observer and intra-observer variation.  
Additionally, current mammographic films are 2-dimensional, which restricts the ability to fully 
appreciate the volume of the breast and the subsequent dense area.  Potential methods to improve 
density measures are underway and could help to improve the understanding between density 
and the risk of breast cancer(10, 26, 40). 
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  In tandem with the evidence linking estrogen and breast cancer(16), there is a body of 
evidence that alludes to specific estrogen metabolites and their respective role in breast cancer 
risk.  Specifically, estrogen metabolism in humans entails the formation of 2-hydroxyestrone (2-
OH), 4-hydroxyestrone (4-OH), and 16alpha-hydroxyestrone (16α-OH) from estrone.  Relative 
to 2-OH, the 16α-OH product possesses estrogenic and genotoxic properties(55, 57).  Because 2-
OH and 16α-OH are complimentary metabolic products derived from a fixed substrate pool, any 
genetic or environmental factor that increases enzymatic production of one metabolite can be 
expected to reduce enzymatic production of the alternative metabolite.  It has therefore been 
postulated that women with high blood or tissue levels of 16α-OH or low 2-OH relative to 16α-
OH have an increased breast cancer risk.  Although the epidemiologic evidence is not universally 
supportive (15), several case-control studies(18, 27, 30, 56) and at least one prospective 
study(38) are consistent with the hypothesized association between the estrogen metabolites and 
breast cancer risk.  To date, there has been one study that has evaluated the relationship between 
estrogen metabolism and breast density.  Riza et al evaluated the role of estrogen metabolites and 
their relationship with high-density Wolfe mammographic parenchymal patterns (P2/DY).  The 
study was nested within a large cross-sectional survey on determinants of mammographic 
patterns carried out in a population-based breast-screening program in Northern Greece. Urinary 
levels of 2-OH and 16α-OH were measured in a random sample of 70 postmenopausal women 
with P2/DY mammographic patterns and in a random sample of 70 postmenopausal women with 
N1 mammographic patterns, individually matched to the P2/DY women on year of birth, years 
since menopause and date of urine collection. Women with a P2/DY pattern had 58% higher 
levels of 2-OH (P = 0.002) and 15% higher levels of 16α-OH (P = 0.37) than those with an N1 
pattern. The ratio of 2-OH:16α-OH was 35% higher (P = 0.005) in women with a P2/DY pattern. 
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 Women in the highest one-third of this ratio were six times more likely to have a P2/DY pattern 
than those in the lowest one-third after adjusting for potential confounders (prevalence odds 
ratio, 6.2; 95% CI, 1.7-22.9; test for linear trend, P = 0.002). These findings seem to suggest that 
a high, rather than a low, 2-OH:16α-OH ratio may be associated with an increase in breast 
cancer risk in postmenopausal women, an increase in breast caner risk than manifests as an 
increase in breast density(43). 
In light of the above-mentioned findings, we examined the joint distribution of breast 
density and serum estrogen metabolite levels in groups of women with and without breast 
cancer, in an attempt to understand the independent and joint effects of breast density and 
estrogen metabolites on breast cancer risk. 
 
4.3   Materials and Methods 
4.3.1 Study Population 
Subjects eligible for study included pre- and post-menopausal women with no personal history of 
cancer (except non-melanoma skin cancer). Volunteers arose from three sources: 1) women 
undergoing outpatient needle breast biopsy through the Breast Biopsy Service at Magee-
Womens Hospital (Pittsburgh, Pennsylvania), 2) women seen in the Magee-Womens Surgical 
Clinic for an initial evaluation after biopsy diagnosed breast cancer, and 3) women receiving 
screening mammography through Magee-Womens Hospital or through a suburban Pittsburgh 
Magee Womancare Center. To identify and recruit eligible subjects, a research assistant 
personally solicited women visiting the Breast Biopsy Service between September 2001 and May 
2004, women visiting the Magee-Womens Surgical Clinic between June 2003 and May 2004, 
and women visiting Magee-Womancare Center – North (Wexford, Pennsylvania) and East 
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 (Monroeville, Pennsylvania) between July 2002 and September 2003.  To boost subject 
recruitment, Magee-Womens Hospital attached study flyers to screening result reports mailed to 
Magee-Womancare Center patrons with negative mammography between November 2003 and 
May 2004. 
Of approximately 750 Breast Biopsy Service patients approached, 404(54% of 750) women 
with no personal cancer history, signed a written consent form, completed a personal interview, 
and produced a blood sample. A subsequent review of breast biopsy pathology reports verified a 
non-breast cancer outcome in 313 (77% of 404) women and a breast cancer outcome in 91 (23% 
of 404).  Subsequently, 192 (61.3% of 313) controls and 80 (88% of 91) breast cancer cases, had 
serum estrogen metabolite and breast density results available. Approximately 200 women were 
approached in the Surgical Clinic, of which 135 women were newly diagnosed with breast 
cancer.  Of those newly diagnosed, 121 (90%) were enrolled and 94 (78% of 121) had serum 
estrogen metabolite and breast density results available.  At Magee-Womancare Centers – North 
and East, approximately 100 patrons were approached directly; 78 (78% of 100) women with no 
personal cancer history, signed a written consent form, completed a personal interview, and 
produced a blood sample. Subsequent follow-up verified non-breast cancer outcomes in 77 
(98.7% of 78) women and a breast cancer outcome in one (1.3% of 78).  Of these, 71 (92.2% of 
77) and 1 (100% of 1) woman have serum estrogen metabolite and breast density results 
available. Finally, mailing study fliers to 6482 women produced 240 (3.7% of 6482) responses, 
including 228 (95.0% of 240) responses from women without a personal cancer history. 130 
(57.0% of 228) women signed a written consent form, completed a study visit with personal 
interview, and produced a blood sample. Of these, 117 women (90.0% of 130) without breast 
cancer and 1 woman (100% of 1) with breast cancer had serum estrogen metabolite and breast 
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 density results available. Therefore, the final study sample included 380 controls consisting of 
192 (50.5%), 71 (18.7%), and 117 (30.8%) women, and 176 cases consisting of 80 (45%), 94 
(53%), 1 (0.8%), and 1 (0.8%) woman from the Breast Biopsy Service, Magee-Womens Surgical 
Clinic, Magee-Womancare Center – North/East, and mass mailings, respectively.  Breast biopsy 
reports were reviewed for all subjects recruited through the breast biopsy service to verify 
presence or absence of breast cancer. 
Every subject included in this study signed a written informed consent document approved 
by the Magee-Womens Hospital Institutional Review Board. 
 
4.4 Data Collection 
Information collected at personal interview and recorded on standardized study forms included 
age, race, menopausal status (including age at menopause and cause (surgical vs. natural)), 
history of treatment with estrogen or progesterone, weight without shoes or heavy clothing 
(measured in kilograms with a standard balance beam scale), and height without shoes at full 
inspiration (measured in centimeters with a stadiometer). Additional information collected 
through the standardized self-administered take-home questionnaire included reproductive 
history (age at menarche, age of first pregnancy lasting at least six months, and number of births) 
and family cancer history. Questionnaires were edited for completeness and consistency. A 
research assistant telephoned subjects, when necessary, to retrieve missing information and to 
resolve inconsistencies. When subjects could not be reached, a research assistant attempted to 
retrieve missing information through review of written medical records. 
The data from pathology reports was double extracted and recorded onto standardized study 
forms in order to simplify data entry.  For cases, recorded data included: in situ versus invasive 
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 cancer, primary tumor size, number of involved axillary lymph nodes, metastasis, estrogen and 
progesterone receptor status, and HER-2/neu oncoprotein status.  
4.4.1 Breast Density  
A consultant reader (Ms. Martine Salane), initially trained by Wolfe, measured both Wolfe’s 
classification and percent breast density from copies of screen-film mammograms obtained 
within six months of study entry. First, visually inspecting the mammogram copies, the reader 
placed each subject into one of the four Wolfe parenchymal pattern categories: N1, P1, P2 and 
DY.  The second breast density method expressed area of visibly dense breast as a percentage of 
the total breast area on a two-dimensional mammogram image. Using the mammogram image 
showing the craniocaudal projection and excluding biopsy scars, Cooper’s ligaments, and breast 
masses, the reader used a wax pencil to outline the entire breast and the portions of breast 
containing radio-densities. The reader used a compensating polar planimeter (LASICO, Los 
Angeles, CA) and traced the outline of the entire breast and outlines of dense breast to compute 
total breast area and dense breast area, respectively.  With respect to cases, the unaffected side 
was sent for evaluation.  For those controls that were recruited from the biopsy clinic, the film 
for the breast not biopsied was used for density evaluation.  All films were relabeled with a study 
ID to ensure that the reader remained blinded to the subject’s identity and case-control status.  
Unknown to the reader, 28 randomly selected mammograms were re-sent at a later date to 
determine reproducibility of the density readings. The intraclass correlation coefficients for intra-
observer agreement were 0.86, 0.99, and 0.89 for dense breast area, total breast area, and breast 
density percent, respectively. 
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4.4.2 Laboratory Measurements 
We used the laboratory of TL Klug and enzyme immunoassays (Immuna Care Corporation, 
Bethlehem, PA; ESTRAMETTM 2/16 ELISA,) to measure the 2-OH and 16α-OH estrogen 
concentrations in serum stored at -70°C and subjected to a single freeze-thaw cycle. The 
ESTRAMET 2/16 ELISA assay has been validated against gas chromatography/mass 
spectroscopy in pooled serum spiked with known amounts of 2-OH and 16α-OH estrogen. The 
analytic sensitivities of the 2-OH and 16α-OH estrogen immunoassays are 20 pg/mL and 10 
pg/mL, respectively. Using control sera, the laboratory reported within-assay coefficients of 
variation of 17% and 9% for 2-OH and 16α-OH concentration, respectively. The inter-assay 
coefficients of variation calculated from the analytic results for blinded duplicate serum samples 
from 25 postmenopausal subjects were 13.9% and 4.0% for 2-OH and 16α-OH concentration, 
respectively. 
 
4.5 Statistical Analysis 
Analyses were conducted for three distinct sub-groups: pre-menopausal women, post-
menopausal women not taking HT, and post-menopausal women taking HT.  The statistical 
significance of group differences with respect to discrete and continuous measures was evaluated 
using the chi-square and Wilcoxon tests, respectively.  Estrogen metabolite measures were 
logarithm-transformed to produce variables distributed more favorably for parametric statistical 
testing. To estimate a geometric mean and 95% confidence interval for a geometric mean 
metabolite measure, we took the exponential of the corresponding mean and 95% confidence 
interval for the mean logarithm-transformed metabolite measure. We used least square methods 
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 (LSMEAN reported by SAS PROC GLM with OM option) to adjust mean breast density and 
geometric mean estrogen metabolite measures for age, BMI, and other factors of interest. We 
used ANOVA type III tests (as reported by SAS PROC GLM) to assess the statistical 
significance of case-control differences with respect to breast density and estrogen metabolite 
measures, unadjusted or adjusted for age, BMI, and other factors of interest.  
The primary research hypothesis involved testing the association between breast density 
and case-control status, before and after adjustments for the estrogen metabolite measures.  
Crude odds ratios (OR) with 95% confidence intervals (95% CI) were calculated across breast 
density across tertiles using unconditional logistic regression.  The tertiles were derived from the 
control population for each of the three separate groups: premenopausal women, postmenopausal 
women not taking HT, and postmenopausal women on HT.  Multivariate logistic regression was 
used to adjust the breast density-breast cancer association for each of the estrogen metabolites, 
age, BMI, and other statistically significant breast cancer risk variables (p <0.10) identified in 
univariate analyses.  All tests of statistical significance were two-tailed.  Probability values of < 
0.05 were considered statistically significant. Statistical analysis was performed with the SAS 
System for Windows, Release 8.02.  
 
4.6 Results 
Table 1 enumerates case and control subjects according to the major study sub-groups.  In situ 
cancer accounted for 21.8%, 14.9%, and 60.0% of the pre-menopausal, post-menopausal, no-HT, 
and post-menopausal-HT cases, respectively (Table 2). Estrogen receptor status was similar 
among pre-menopausal and post-menopausal, no HT with 76.5% and 80.9% receptor positive 
respectively.  Post-menopausal, HT users were predominantly estrogen receptor positive 
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 (93.7%).  Progesterone receptor status was similar across all sub-groups.  With respect to age, 
BMI, age at menarche, and pregnancy history, distributions were similar across case-control 
status within the study sub-groups (Table 3).  Additionally, age at first pregnancy, parity, 
smoking, age at menopause, type of menopause, and family history of cancer, were evaluated 
and were similar across case-control status and study sub-groups.  Compared to controls (Table 
4), cases had greater median breast density percent across all sub-groups while only significant 
in the pre-menopausal group (p=0.006).  Lower 2-OH levels were noted in all case groups, but a 
statistically significant difference was noted only among pre-menopausal (p=0.032) and post-
menopausal, no HT (p=0.022).  The 16α-OH levels were lower in the pre-menopausal cases, but 
higher in both post-menopausal groups, but these associations were not statistically significant.  
With respect to the ratio, the pre-menopausal and post-menopausal no HT cases demonstrated a 
lower ratio, while only the post-menopausal no HT cases were significantly different (p=0.023).  
In post-menopausal HT cases, the 2:16 ratio was higher than controls, although not statistically 
significant.     
In Table 5, the unadjusted and adjusted mean breast density and geometric mean estrogen 
metabolite levels are illustrated.  The mean breast density percent remained greater in the pre-
menopausal cases versus controls even after adjustment for age, BMI, and the estrogen 
metabolites (p=0.013).  Additionally, lower 2-OH levels were noted in the pre-menopausal cases 
versus controls even after adjustment for age and BMI.  In the post-menopausal, no HT users, 
cases had lower 2-OH and 2:16 ratio levels compared to controls even after age and BMI 
adjustment.  No significant difference in mean breast density percent or 16α-OH was noted 
between cases and controls.  With respect to mean breast density percent and the estrogen 
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 metabolite levels, no significant difference was evident between cases and controls in post-
menopausal HT users.   
Finally, Tables 6-7 provide the odds ratio (OR) that describes the association between breast 
density tertile and breast cancer risk, unadjusted and adjusted for estrogen metabolites and breast 
cancer risk covariates.  In premenopausal women (high density tertile vs. low density tertile), the 
OR ranged from 3.07 (95%CI 1.38-7.30) to 5.63 (95% CI 1.94-16.36) adjusting for BMI, 
estrogen metabolites and reproductive factors (ever pregnant, parity).  Postmenopausal women 
not taking HT, had greater OR 1.63-1.91 inclusive of the adjustment for age, BMI, pregnancy 
history, parity, and estrogen metabolites in the mid vs. low tertile compared to the high vs. low 
tertile OR (0.85-1.27).  Breast cancer associated weakly with breast density (high vs. low tertile) 
in postmenopausal women on HT (OR 0.88-1.64). 
 
4.7 Discussion 
Breast density and estrogen metabolism have both been implicated in the risk of developing 
breast cancer.  Our main aim was to evaluate the extent to which adjustments for serum estrogen 
metabolite levels change the association between density and risk.   
In this study, premenopausal women in the highest tertile of percent breast density were at a 
3-4-fold increase risk of breast cancer when compared to women with the least dense breast 
tissue. This finding is consistent with previous reports (8, 10, 49).  Moreover, we found that the 
association between breast density and risk of breast cancer was independent of the estrogen 
metabolites, age, BMI, and age at menarche.   
Mammographic breast density serves as an estimate of the proportion of fibroglandular 
tissue to fat in the breast.  Premenopausal women, compared to postmenopausal women, 
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 generally have greater breast density secondary to a higher proportion of glandular tissue.  As 
women age, fatty tissue replaces glandular tissue therefore decreasing breast density(13, 23, 28, 
31).  Consistent with this theory, reports in the literature illustrate a decrease in mammographic 
breast density with age, especially after the menopause(25).   
Several epidemiological studies have reported breast density to be strongly associated with 
postmenopausal breast cancer risk (8, 10, 49).  Although we did observe an increase in breast 
cancer risk with increase in percent density, the magnitude of the association was weak and not 
statistically significant in either the unadjusted or adjusted models. After adjustment for age, the 
trend toward increased risk with higher breast density became evident suggesting that age is 
confounding the association between breast density and breast cancer in the postmenopausal 
setting.  With the addition of other breast cancer risk covariates including ever pregnant and 
parity, the trend for risk increased.  This is consistent with the literature which has reported an 
association between early age at menarche, nulliparity, later age at first birth, and parity(2, 19, 
22, 46, 48) with both increased breast cancer risk and greater breast density in pre- and post-
menopausal women. With respect to breast density, pregnancy is associated with a change in 
breast structure to more differentiated lobules with less cell proliferation with the greatest effect 
on breast structure obtained from the first pregnancy, and further differentiation with each 
subsequent pregnancy(44).   
The fact that in our population, breast density in postmenopausal women was not 
significantly associated with breast cancer risk may be a result of inadequate sample size or the 
inability to determine if years since menopause is confounding the association given that 39% of 
postmenopausal women not on HT were missing this information.   
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 Furthermore, consistent with the literature, the use of HT was associated with increased 
breast density (Table 4).  Several studies have reported an increase in breast density with the use 
of HT, in particular the combination of estrogen and progesterone(37).   
It has been reported in the literature that low 2-OH levels and higher 16α-OH levels are 
associated with an increased risk of breast cancer(27, 30, 38, 39, 45, 56).  However, not all 
studies have found this association(15, 51).  To date, there has been only one study to report on 
the relationship between estrogen metabolites and breast density.  Riza et al(43) evaluated the 
role of estrogen metabolites and their relationship with high-density Wolfe mammographic 
parenchymal patterns (P2/DY).  The reported findings suggest that a high, rather than a low 2-
OH:16α-OH ratio may be associated with an increase in breast cancer risk in postmenopausal 
women, which is opposite to that which would be expected.   
Adjustments for 2-OH and 16α-OH produced no more than small decreases in associations 
observed between breast density and pre-menopausal breast cancer risk (Table 7). If breast 
density functioned primarily as a biological measure of estrogen metabolite status and if the 
metabolites acted as the proximate cause of breast cancer, adjustments for metabolite 
concentrations might have been expected to attenuate the breast density-breast cancer risk 
association to a greater extent. 
There are several features of the present study that warrant discussion. Study limitations 
include the use of single measurement of serum estrogen metabolites and breast density. 
Estrogen metabolite levels in premenopausal women may be subject to fluctuations in the 
menstrual cycle.  As we were unable to determine the phase at time of blood draw, variability 
may exist among pre-menopausal women with respect to the estrogen metabolite measures and 
the respective breast density measurement.  Reproductive and lifestyle factors were obtained by 
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 self-report which may lend to recall bias, thereby attenuating our results.  Finally, we cannot 
exclude the possibility that our findings may be due to chance or confounded by some 
unidentified factor.  Strengths of this study include histologically confirmed breast cancer cases, 
and the use of a single, expert breast density reader, which helps to reduce variability in breast 
density measurements and subsequent measures of effect. 
In conclusion, this is the first study to investigate the association between breast density, 
serum estrogen metabolites, and breast cancer risk factors in pre-and post-menopausal women.  
A breast density-breast cancer risk relationship, that is independent of blood estrogen metabolite 
concentrations, exists in subgroups of women classified according to menopausal status and HT 
use.  Additional studies are needed to clarify the relationship between breast density, estrogen 
metabolism and breast cancer risk.   
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 Table 4-1: Study sub-groups according to menopausal status and hormone therapy use 
 
 Control Case 
Study sub-group N Percent N Percent 
Pre-menopausal 124 33.1 55 31.6 
P
P
ost-menopausal, no HT 159 42.4 94 54.0 
ost-menopausal, HT 92 24.5 25 14.4 
 
Abbreviations: HT – Current hormone therapy 
Notes: 
1. Table excludes five control and two case post-menopausal subjects with missing HT 
status. 
 2. p = 0.009 (chi-square test), case-control difference with respect to sub-group. 
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 Table 4-2: Breast cancer cases according to type of cancer, stage, and 
estrogen/progesterone receptor status 
         
      Pre-menopausal  Post-menopausal, no HT  Post-menopausal, HT 
   N % N % N % 
Cancer type        
In s
Invasive  
Unknown  
In s
I  
II 
III 
IV  
Unknown  
Negative*  
Pos
Unknown  
itu  12 21.8 14 14.9 15 60.0 
43 78.2 80 85.1 10 40.0 
Stage        
12  12  5  
itu  9 20.9 12 14.6 12 60.0 
21 48.8 50 61.0 4 20.0 
 10 23.3 17 20.7 3 15.0 
 3 7.0 3 3.7 1 5.0 
0 0 0 0.0 0 0.0 
Estrogen Receptor        
4  5  9  
12 23.5 17 19.1 1 6.3 
itive**  39 76.5 72 80.9 15 93.7 
Progesterone Receptor       
4  5  9  
Negative†  13 25.5 35 39.3 4 25.0 
 
1. Table excludes two case post-menopausal subjects with missing HT status. 
2. Table excludes twelve pre-menopausal case, ten post-menopausal-no HT case, and two 
post-menopausal,-HT case subjects because of missing stage. 
 
3. Table excludes four pre-menopausal case, three post-menopausal-no HT case, and nine 
post-menopausal,-HT case subjects because of missing estrogen receptor and progesterone 
receptor status. 
 
* Includes 1 in situ, 1 in situ, and 1 in situ in pre-menopausal, post-menopausal, No HT, and 
post-menopausal, HT respectively 
** Includes 7 in situ, 11 in situ, and 6 in situ in pre- menopausal, post-menopausal, No HT, and 
post-menopausal, HT respectively 
† Includes 1 in situ, 3 in situ, and 2 in situ in pre- menopausal, post-menopausal, No HT, and 
post-menopausal, HT respectively 
‡ Includes 7 in situ, 9 in situ, and 5 in situ in pre- menopausal, post-menopausal, No HT, and 
post-menopausal, HT respectively 
      Positive‡   38 74.5  54 60.7  12 75.0 
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 Table 4-3: Cases and controls distributed according to age and three determinants of breast density  
 Pre-menopausal  Post-menopausal, no HT  Post-menopausal, HT 
 Control  Case   Control  Case   Control  Case  
 N %  N N N N% P  %  N % P  %  % P 
Age (tertile)      0.923       0.085       0.214
L
M
H
<
2
3
<
1
n
e
ow 39 31.5 18 32.7  55 34.6  28 29.8  35 38.0 5 20.0  
iddle 43 34.7 20 36.4  53 33.3  23 24.5  29 31.5 9 36.0  
igh 42 33.9 17 30.9  51 32.1  43 45.7  28 30.4 11 44.0  
BMI (kg/m2)      0.499       0.721       0.687
25 52 41.9 26 47.3  54 34.0  30 32.3  26 28.6 9 36.0  
5.0-34.9 42 33.9 20 36.4  53 33.3  28 30.1  41 45.1 9 36.0  
5.0+ 30 24.2 9 16.4  52 32.7  35 37.6  24 26.4 7 28.0  
Age menarche (years)      0.353       0.528       0.055
13 68 56.2 35 63.6  72 45.6  39 41.5  39 42.9 15 65.2  
3+ 53 43.8 20 36.4  86 54.4  55 58.5  52 57.1 8 34.8  
Pregnancy history      0.885       0.321       0.347
ever pregnant 19 16.1 8 17.0  24 15.7  10 11.1  14 16.1 5 25.0  
ver pregnant 6+ months 99 83.9 39 83.0  129 84.3  80 88.9  73 83.9 15 75.0  
Abbreviations: HT – Current hormone therapy; P – statistical significance (p-value; chi-square test) of case-control differences; BMI – Body 
mass index 
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 Notes: 
1. Table excludes five control and two case post-menopausal subjects with missing HT status. 
2. BMI missing for one post-menopausal-no HT case and one post-menopausal,-HT control subject. 
3. Age at menarche missing for three pre-menopausal control, one post-menopausal-no HT control, one post-menopausal-HT control, and 
two post-menopausal-HT case subjects. 
4. Pregnancy history missing for three pre-menopausal control, three pre-menopausal case, one post-menopausal-no HT control, one post-
menopausal-no HT case, two post-menopausal-HT control, and three post-menopausal-HT case subjects. 
5. Ever pregnant, but never for 6+ months, for three pre-menopausal control, five pre-menopausal case, five post-menopausal-no HT 
control, three post-menopausal-no HT case, three post-menopausal-HT control, and two post-menopausal-HT case subjects. 
6. Low, middle, and upper  menopause- and HT-specific age tertiles defined according to age distribution in the control group, as follows, 
<44, 44-47, and 48+ year-old women, if pre-menopausal, <57, 57-62, and 63+ year-old women, if post-menopausal not on HT, or <56, 
56-60, and 61+ year-old women, if post-menopausal on HT. 
.
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 Table 4-4: Breast density and estrogen metabolite measures, according to case-control status and study sub-group 
 
 Pre-menopausal  Post-menopausal, no HT  Post-menopausal, HT 
 Control Case P  Control Case P  Control Case P 
N 124 55   159 94   92 25  
Breast density (%)            
Median 41.1 50.3 0.006  27.0 30.8 0.827  37.1 38.2 0.634
IQR 25.6-55.7 41.4-65.9   12.7-46.1 
16.9-
39.9   24.6-50.9 
27.5-
51.4  
Range 0.0-92.2 3.5-85.9   0.0-85.7 
0.0-
68.1   0.0-84.0 
0.0-
77.2  
Mean 41.2 50.0   30.7 29.4   36.7 38.8  
95% CI 37.6-44.9 44.5-55.4   27.5-34.0 
26.3-
32.5   32.8-40.7 
30.9-
46.7  
2-OH (pg/ml)            
Median 251 187 0.032  158 140 0.022  348 287 0.800
IQR 163-388 118-308   117-218 99-183   194-472 
193-
638  
Range 43-897 50-680   33-1170 40-778   59-2058 
71-
1269  
Geometric mean 243 195   161 140   308 325  
95% CI 218-270 167-228   149-175 
126-
155   266-357 
239-
442  
16α-OH (pg/ml)            
Median 422 389 0.073  351 364 0.536  412 439 0.881
IQR 374-480 345-502   316-426 
319-
413   356-524 
351-
493  
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Table 4-4 (Continued) 
 
Abbreviations: HT – Current hormone therapy; P – statistical significance (p-value; Wilcoxon) of case-control differences; BMI – 
Body mass index 
Notes: 
1. Table excludes five control and two case post-menopausal subjects with missing HT status. 
Range 262-836 280-659   129-923 
253-
734   290-1502 
280-
773  
Geometric mean 432 406   366 370   444 440  
95% CI 416-449 384-430   351-382 
356-
385   417-474 
396-
490  
2-OH:16α-OH ratio            
Median 0.53 0.50 0.123  0.43 0.37 0.023  0.74 0.80 0.661
IQR 0.40-0.83 0.33-0.78   0.31-0.59 
0.28-
0.50   0.47-1.10 
0.44-
1.42  
Range 0.14-1.85 0.15-1.56   0.10-2.72 
0.09-
2.02   0.16-2.52 
0.15-
1.90  
Geometric mean 0.56 0.48   0.44 0.38   0.69 0.74  
0.51-0.62 0.42-0.55   0.41-0.48 
0.34-
0.42 95% CI   0.61-0.79 
0.56-
0.97  
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Table 4-5: Mean breast density and geometric mean estrogen metabolite measures in cases and controls 
 Unadjusted  Age- and BMI-adjusted  
Age-, BMI, 2-OH, and 
16α-OH adjusted 
 Control Case P-value  Control Case P-value  Control Case P-value
Pre-menopausal            
N 124 55          
Breast density (%, mean) 41.2 50.0 0.010 41.7 48.8 0.016 41.8 48.7 0.013 
2-OH (pg/ml, geometric mean) 243 195 0.027 243 194 0.022     
16α-OH (pg/ml, geometric mean) 432 406 0.086 431 407 0.108     
2-OH:16α-OH ratio (geometric mean) 0.56 0.48 0.080 0.56 0.48 0.060     
Post-menopausal, No HT            
N 158 94          
Breast density (%, mean) 30.7 29.3 0.562 30.2 30.3 0.963 30.1 30.3 0.944 
2-OH (pg/ml, geometric mean) 161 139 0.031 161 139 0.037     
16α-OH (pg/ml, geometric mean) 366 371 0.694 366 372 0.638     
2-OH:16α-OH ratio (geometric mean) 0.44 0.38 0.018 0.44 0.38 0.020     
Post-menopausal, HT            
N 25 91          
Breast density (%, mean) 36.8 38.8 0.656 36.9 38.4 0.715 36.9 38.4 0.708 
2-OH (pg/ml, geometric mean) 309 325 0.773 311 319 0.880     
16α-OH (pg/ml, geometric mean) 446 440 0.857 444 446 0.956     
2-OH:16α-OH ratio (geometric mean) 0.69 0.74 0.674 0.70 0.71 0.882     
Abbreviations: HT – Current hormone therapy; BMI – Body mass index 
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Notes: 
1. Table excludes five control and two case post-menopausal subjects with missing HT status. 
2. Table excludes one post-menopausal-no HT case and one post-menopausal,-HT control subject because of missing BMI. 
3. Age-adjustment according to menopausal status and HT-specific age tertile category treated as a class variable, as determined by 
the age distribution in the control group. Low, middle, and upper age tertiles include <44, 44-47, and 48+ year-old women, if 
pre-menopausal, <57, 57-62, and 63+ year-old women, if post-menopausal not on HT, or <56, 56-60, and 61+ year-old women, 
if post-menopausal on HT. 
4. BMI-adjustment according to BMI category (<25, 25-29, and 30+ kg/m2), treated as a class variable. 
5. Age tertile by BMI interaction effect not statistically significant (in SAS PROC GLM) in all models examined. Therefore, age- 
and BMI-adjustments ignore any age by BMI interaction. 
6. 2-OH and 16α-OH adjustments according to log-transformed concentration values treated as continuous variables. 
7. Adjusted means and geometric means based on least square mean (LSMEAN) reported by SAS PROC GLM with OM option. 
8. Statistical significance of case-control differences based on TYPE III test, as reported by SAS PROC GLM. 
9. Tabulated values for the mean adjusted breast density allowed negative values for adjusted breast density. Recoding adjusted 
breast density percent for one pre-menopausal control (from -4.3% to 0%) increased mean adjusted breast density to 41.8%. 
Recoding adjusted breast density percent for three post-menopausal-no HT controls (from –4.8%, -5.5%, and –6.4% to 0%) 
increased mean adjusted breast density to 30.3%
  
Table 4-6: The odds ratio (OR) unadjusted and adjusted for age, BMA and selected breast 
cancer risk variables
 Breast density tertile  
Breast density 
percent** 
 Low Mid High p-trend  
Pre-menopausal      
cases 10 14 31   
control 42 41 41   
  1.43 3.18   
OR (95% CI)1 reference 1.43 (0.57-3.59) 3.18 (1.38-7.30) 0.01 1.36 (1.07-1.72) 
OR (95% CI)2  1.50 (0.59-3.80) 3.35 (1.43-7.87) <0.01 1.37 (1.08-1.74) 
OR (95% CI)3  1.51 (0.56-4.07) 4.69 (1.65-13.37) 0.05 1.33 (0.99-1.77) 
OR (95% CI)4  1.48 (0.55-3.99) 5.63 (1.94-16.36) 0.03 1.38 (1.03-1.85) 
      
Post-menopausal, no HT      
cases 26 44 24   
control 52 54 53   
OR (95% CI)1  1.63 (0.88-3.12) 0.91 (0.46-1.78) 0.60 0.95 (0.77-1.16) 
OR (95% CI)2  1.80 (0.96-3.39) 1.19 (0.58-2.46) 0.87 0.98 (0.79-1.21) 
OR (95% CI)3  1.90 (0.98-3.69) 1.18 (0.49-2.83) 0.78 1.03 (0.82-1.30) 
OR (95% CI)5  
 
1.91 (0.97-3.76) 1.27 (0.50-3.19) 0.56 1.08 (0.84-1.37) 
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 Table 4-6 (continued) 
 
Post-menopausal, HT      
cases 7 9 9   
control 31 31 30   
OR (95% CI)1  1.29 (0.43-3.89) 1.33 (0.44-4.02) 0.64 1.09 (0.77-1.53)
OR (95% CI)2  1.31 (0.41-4.14) 1.35 (0.44-4.16) 0.66 1.08 (0.76-1.52)
OR (95% CI)3  1.07 (0.28-4.07) 1.64 (0.44-6.19) 0.57 1.12 (0.76-1.67)
OR (95% CI)5  1.11 (0.25-4.91) 0.88 (0.15-5.16) 0.84 0.96 (0.62-1.47)
      
HT=Hormone therapy      
1. Unadjusted, all subjects     
2. Adjusted for age      
3. Adjusted for age and BMI     
4. Adjusted for age, BMI, and menarche     
5. Adjusted for age, BMI, Ever Pregnant, Parity    
*Odds of breast cancer among women with mid and high tertile breast density percent relative to 
women with low tertile breast density percent 
**Increase in odds of breast cancer per 15% increase in breast density percent   
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 Table 4-7: The odds ratio (OR) unadjusted and adjusted for estrogen metabolites 
and BMI 
 Breast density tertile  
Breast density 
percent** 
 Low Mid High p-trend  
Pre-menopausal      
cases 10 14 31   
control 42 41 41   
      
OR (95% CI)1 reference 1.43 (0.57-3.59) 3.18 (1.38-7.30) 0.01 1.36 (1.07-1.72)
OR (95% CI)2  1.56 (0.61-3.99) 3.19 (1.39-7.37) 0.01 1.37 (1.08-1.75)
OR (95% CI)3  1.33 (0.52-3.39) 3.07 (1.33-7.09) 0.01 1.35 (1.06-1.72)
OR (95% CI)4  1.43 (0.55-3.70) 3.12 (1.35-7.25) 0.01 1.36 (1.07-1.74)
OR (95% CI)5  1.44 (0.54-3.82) 4.35 (1.57-12.08) 0.05 1.32 (0.99-1.76)
OR (95% CI)6  1.51 (0.55-4.19) 4.17 (1.49-11.69) 0.06 1.32 (0.99-1.76)
OR (95% CI)7  1.32 (0.48-3.61) 4.14 (1.48-11.61) 0.06 1.32 (0.99-1.76)
      
      
Post-menopausal, no HT      
cases 26 44 24   
control 52 54 53   
OR (95% CI)1  1.63 (0.88-3.12) 0.91 (0.46-1.78) 0.60 0.95 (0.77-1.16)
OR (95% CI)2  1.65 (0.88-3.09) 0.93 (0.47-1.84) 0.68 0.96 (0.78-1.18)
OR (95% CI)3  1.64 (0.88-3.04) 0.89 (0.45-1.76) 0.59 0.95 (0.77-1.16)
OR (95% CI)4  1.65 (0.88-3.08) 0.92 (0.46-1.82) 0.67 0.96 (0.78-1.18)
OR (95% CI)5  1.67 (0.88-3.17) 0.89 (0.39-2.04) 0.94 0.99 (0.79-1.24)
OR (95% CI)6  1.69 (0.88-3.23) 0.90 (0.39-2.08) 0.97 0.99 (0.79-1.25)
OR (95% CI)7  1.69 (0.89-3.21) 0.85 (0.37-1.97) 0.92 0.99 (0.79-1.24)
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 Table 4-7 continued 
 
 
 
 
     Post-menopausal, HT 
Cases 7 9 9   
Control 31 31 30   
OR (95% CI)1  1.29 (0.43-3.89) 1.33 (0.44-4.02) 0.64 1.09 (0.77-1.53)
OR (95% CI)2  1.12 (0.36-3.49) 1.41 (0.46-4.32) 0.66 1.08 (0.77-1.53)
OR (95% CI)3  1.31 (0.44-3.98) 1.38 (0.45-4.20) 0.63 1.09 (0.77-1.54)
OR (95% CI)4  1.14 (0.36-3.56) 1.41 (0.46-4.33) 0.64 1.09 (0.77-1.54)
OR (95% CI)5  1.07 (0.31-3.67) 1.50 (0.41-5.46) 0.58 1.12 (0.76-1.65)
OR (95% CI)6  1.04 (0.30-3.61) 1.48 (0.41-5.38) 0.57 1.12 (0.76-1.65)
OR (95% CI)7  1.08 (0.31-3.77) 1.48 (0.41-5.37) 0.57 1.12 (0.76-1.66)
      
HT=Hormone therapy      
BMI=Body mass index      
1. Unadjusted, all subjects      
2. Adjust ln(2-OH)      
3. Adjust ln(16-OH)      
4. Adjust ln(2-OH) and ln(16-OH)     
5. Adjust BMI      
6. Adjust BMI and ln(2OH)      
7. Adjust BMI and ln(16OH)     
*Odds of breast cancer among women with mid and high tertile breast density percent relative 
to women with low tertile breast density percent 
**Increase in odds of breast cancer per 15% increase in breast density percent  
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5. GENERAL DISCUSSION 
 
5.1. Breast Cancer Statistics 
In the year 2005, breast cancer will account for 32% (211,240 new cases) of all cancer cases in 
women in the United States with 41,514 deaths attributed to breast cancer(20).  Assuming a life 
expectancy of 85 years, it is estimated that the lifetime risk of developing breast cancer is one in 
eight for American women with the risk rising considerably for women who have pre-existing 
risk factors including older age, family history of breast cancer, BRCA1 and BRCA2 gene 
mutations, or a history of biopsy proven precursor lesions(36).  Incidence and mortality rates 
differ greatly among ethnic groups.  Among black women in the United States, the age-
standardized incidence rate is lower than the rate in white women with 119.9 per 100,000 cases 
and 141.7 per 100,000 respectively.  Although white women have a higher incidence of breast 
cancer, the mortality is greater in black women (35.4 per 100,000) than white women (26.4 per 
100,000)(20).  In Hispanic, American Indian, and Asian women, both the incidence and 
mortality rates are reportedly lower than both white and black women.  The disparity in 
incidence is believed to be secondary to more frequent mammograms, later age at first birth, and 
greater use of hormone therapy (HT) among white women.  Higher mortality rates among black 
women are thought to reflect later stage at diagnosis, differences in the access for diagnosis and 
treatment, and biological differences, most notably an increased incidence of estrogen receptor 
(ER) negative tumors(20).  While the incidence of breast cancer is higher in women who carry a 
genetic mutation, this only explains approximately two-thirds to three-fourths of familial breast 
cancer which itself makes up 10% of all breast cancer cases(14, 26).  With greater knowledge of 
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 factors affecting risk, an opportunity exists to identify those women who are most likely to 
benefit from the implementation of prevention strategies. 
 
5.2. Breast Density 
Over the past 25 years, there has been a steady increase in the incidence of breast cancer with the 
greatest annual percent change (3.7%) noted between 1980 and 1987 with a subsequent decrease 
to 0.5% between 1987 and 1999.  It has been postulated that the initial increase was related to the 
initiation of the systematic use of mammography and the associated lead-time bias(13, 21).  
Mortality has decreased steadily over the past 25 years and is associated with earlier detection.  
Mammographic sensitivity ranges between 63-87.7% and specificity between 80-90%(3, 12, 15).  
Several factors can influence mammographic sensitivity and specificity including age, HT use, 
and density.  Breast density, in particular, has gained attention in relation to the risk of breast 
cancer.  Outside of age and BRCA1 or BRCA2, density carries the largest risk for breast cancer 
with a four to six-fold increase in risk in those women with dense breast tissue(7, 8).  What 
remains unclear is the best way to measure density.  The first method was proposed by Wolfe in 
1976, consisting of four classifications: N1 radiolucent (fatty) breasts containing few ducts; P1 
ductal (linear) pattern occupying less than 25% of the breast area; P2 ductal (linear) pattern and 
nodular densities occupying more than 25% of the breast area; and the DY radio-density that 
completely obscured the ductal pattern.  Additionally, the breast imaging reporting and data 
systems (BIRADS) is another qualitative classification.  This system also utilizes four categories: 
extremely fatty; scattered density; heterogeneous density; and extremely dense.  Several studies 
have found the Wolfe categories to predict risk and although few studies have utilized the 
BIRADS classification, those reported show a significant increase risk in the extremely dense 
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 category(8).  Other methods of measurement include quantitative approaches which have 
reported consistent results and larger gradients of risk when compared to qualitative methods(8, 
34).  Current quantitative methods include computer-assisted methods, estimation by radiologists 
and planimetry.  Despite current methods of measuring breast density, a standard approach for 
measurement is lacking and methodological limitations are evident.  Both qualitative and 
quantitative methods have an element of subjectivity lending to the possibility of inter-observer 
and intra-observer variation.  Additionally, current mammographic films are 2-dimensional, 
which restricts the ability to fully appreciate the volume of the breast and the subsequent dense 
area.  Potential methods to improve density measures are underway and could help to improve 
the understanding between density and the risk of breast cancer(8, 18, 27). 
 The question as to whether density is associated with a causal mechanism or is just an 
element of masking is not new.  Masking does occur and may increase the risk in the short term, 
but with long term follow-up and repeated screening this effect disappears(8).  In a study 
reported by Byrne et al(11) in which 1880 out of 4000 women developed breast cancer, it was 
noted that some women developed breast cancer as many as 14 years after high density had been 
detected.   
It has also been postulated that the components of breast tissue differ between dense and 
non-dense tissue.  Connective tissue, including collagen and fibroblasts, along with epithelial 
cells are components of dense breast tissue.  Several studies have evaluated the relationship 
between density as it appears radiologically with the histology of breast tissue.  Nine of ten 
studies used samples from a mastectomy or biopsy and six of these studies reported an 
association between density and epithelial proliferation and density and stromal proliferation(2, 
4-7, 10, 16, 32, 35).  A concern was that these samples might not be representative of the general 
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 population.  Li and colleagues reported on a study using samples from women at forensic biopsy 
which revealed a higher percentage of the tissue occupied by cells, glandular structures, and 
collagen in dense breast tissue(4, 8, 22).  
 
5.3. Estrogen and Breast Cancer 
Exposure to endogenous estrogen and its role as a risk factor for breast cancer has been 
consistently reported in the literature(24).  More recently, the metabolism of estrogens has been 
implicated as one of the mechanisms of carcinogenesis secondary to genotoxic and mutagenic 
metabolites(38, 39). It is postulated that the contribution of metabolites to breast cancer is related 
to the presence and formation in breast tissue(38).  Supporting this theory are reports that breast 
tissue levels of estrogen were found to be 10-50 times the levels in blood(33) and higher 
estradiol concentrations were noted in malignant versus nonmalignant tissues in postmenopausal 
women.  This is thought to be reflective of the aromatase activity in breast tissue(19, 38).  
Additionally, evidence that oxidative pathways are active in breast tissue was demonstrated with 
the detection of estrogen metabolites and conjugates ranging from 3 to 13 pmol per gram in 
human breast tissue(29, 38).   Lastly, there is evidence to suggest a relationship between breast 
cancer risk and polymorphisms in genes responsible for encoding the enzymes involved in 
estrogen metabolism(38).    
 The Mammogram and Masses Study (MAMS) provided a unique opportunity to evaluate 
the relationship between mammographic breast density, estrogen metabolism and breast cancer 
risk factors in both cases and controls.  Several studies have evaluated breast density or estrogen 
metabolism in conjunction with breast cancer risk factors, but only one has evaluated breast 
density and estrogen metabolism together(28).  Still, many questions remain regarding the role of 
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 estrogen metabolism, the most appropriate measurement of the metabolite levels and if risk may 
be modified.  Additionally, measurement of density is not standardized and while improved, still 
has limitations.  An extensive questionnaire attempted to capture the multitude of internal and 
external factors that are related to breast cancer risk.  As with many questionnaires, recall bias is 
a potential issue when considering the results.  Density measurements were reported for both 
Wolfe’s method and quantitatively using planimetry to produce percent density (area of 
density/total area of the breast).  Initially, one of the goals of the study was to evaluate the 
interaction between different types of HT (estrogen + progesterone and estrogen only 
formulations) and density and HT and estrogen metabolism.  However, due to the reported 
increase in breast cancer risk released by the Women’s Health Initiative(37), we noted a 
significant decline in HT users rendering the ability to effectively evaluate the association with 
HT use, and in particular differences among HT preparations impossible. 
 
5.4. Article 1 
In the first article, we evaluated the relationship between estrogen metabolite levels and breast 
cancer risk factors, independent of sex-steroid hormones, in an attempt to provide insight into the 
underlying biologic mechanisms.  The population consisted of participants in the Study of 
Osteoporosis and Fractures (SOF), a longitudinal study that evaluated risk factors for 
osteoporosis and falls in 9,704 White women age 65 and older.  They were recruited from 1986-
1988 using population-based lists in Baltimore, MD, Pittsburgh, PA, Minneapolis, MN, and 
Portland, OR.  We included only those cancer free controls who participated in the estrogen 
metabolite study and who also had available sex serum hormones.  Our results revealed 
significant associations between the sex-steroid hormones and estrogen metabolite levels.  The 
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 relationship between weight and 16α-OH and BMI and 16α-OH were statistically significant in 
univariate analyses.  However, in multivariate analyses, these relationships disappeared once we 
controlled for the sex-steroid hormones.  In general, there were no significant relationships 
between the putative breast cancer risk factors and the 2-OH levels and the 2:16 ratio.   We 
found a significant positive relationship between surgical menopause and the 16α-OH 
metabolite, independent of estradiol, testosterone, and SHBG.  Women who had a surgical 
menopause had seven times the odds of having a 16α-OH level in the high versus low tertile 
(OR=7.37, p<0.001).  In a study of 15,844 women, a non-significant increase in breast cancer 
risk was noted in women who underwent gynecologic surgery for endometriosis(30).  Hence, the 
higher 16α-OH associated with surgical menopause may reflect the underlying hormone 
dysregulation associated with the indication for the hysterectomy.  Lastly, in our analyses, we 
found no relationships between traditional risk factors (age, age at menarche, age at first birth, 
age at menopause) and the estrogen metabolite levels.  This may have reflected the small sample 
size.  However, if the metabolites truly cause breast cancer, it does not appear that the 
metabolites are mediating the breast cancer risk effects of the traditional risk factors.    
 
5.5. Article 2 
In the second article, in pre- and post-menopausal women without breast cancer, we endeavored 
to characterize the relationship between breast density and the serum concentrations of two 
major estrogen metabolites (2-OH and 16α-OH).  Subjects eligible for study included pre- or 
post-menopausal women with 1) no personal history of cancer (except skin) and 2) no evidence 
for breast cancer after mammography screening or breast biopsy. Volunteers arose from two 
sources: 1) women undergoing outpatient needle breast biopsy through the Breast Biopsy Service 
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 at Magee-Womens Hospital (Pittsburgh, Pennsylvania) and 2) women receiving screening 
mammography through Magee-Womens Hospital or through a suburban Pittsburgh Magee 
Womancare Center. To identify and recruit eligible subjects, a research assistant personally 
solicited women visiting the Breast Biopsy Service between September 2001 and May 2004 and 
women visiting either the Magee-Womancare Center – North (Wexford, Pennsylvania) or 
Magee-Womancare Center – East (Monroeville, Pennsylvania) between July 2002 and 
September 2003. To boost subject recruitment, Magee-Womens Hospital attached study flyers to 
screening result reports mailed to Magee Womancare Center patrons with negative 
mammography breast imaging reporting and data systems (BIRAD 1 and 2) between November 
2003 and May 2004.  We evaluated premenopausal women, postmenopausal women not on HT, 
and postmenopausal women on HT separately.  We found that the mean percent breast density 
was higher in premenopausal women and postmenopausal women on HT than postmenopausal 
women not taking HT.  BMI was inversely related to breast density percent in all subgroups.  We 
did note in leaner women (BMI <25 kg/m2) higher 2-OH levels in pre-and postmenopausal 
women on HT compared to heavier women, which has been previously reported(23).  
Additionally, leaner postmenopausal women on HT had higher 16α-OH levels(25).  With respect 
to reproductive factors, our results revealed greater percent breast density in nulligravid 
postmenopausal women not on HT than postmenopausal women not on HT with at least one 
pregnancy.  This association remained statistically significant even with adjustment for age 
indicating that age and pregnancy independently influence breast cancer risk.  Mean 16α-OH 
concentrations were higher in nulligravid premenopausal women, although not statistically 
significant.  Menarche occurring at age 13 or greater yielded significantly denser breast tissue 
when compared with women who began menstruatingat <13 years, particularly in the 
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 premenopausal population.  Again, in premenopausal women, only the mean 2-OH:16α-OH 
ratio was associated with an earlier age at menarche vs later menarche, although not statistically 
significant.  Our results revealed associations between the estrogen metabolites and breast 
density, which appeared independent of post-menopausal hormone medication use. However, 
statistical associations disappeared upon control for menopausal status.  Our findings suggest 
that serum estrogen metabolite concentrations and breast density may share common 
determinants that are related to the menopause. Or, estrogen metabolite changes, occurring as a 
consequence of menopause, may directly contribute to the menopause-associated declines in 
breast density.   
 
5.6. Article 3 
In the third article, we comparatively evaluated the association of breast density, estrogen 
metabolites, menopausal status and breast cancer risk factors among breast cancer cases and 
controls using the study as mentioned in article 2 with the addition of breast cancer cases 
confirmed by pathology reports for a total of 178 premenopausal (55 cases, 124 controls) and 
378 post-menopausal (121 cases, 256 controls) women.  .     
Premenopausal women have a 3-4 fold increased risk of breast cancer in those that have 
high tertile breast density vs low tertile density.  Breast density did not appear to substantially 
increase breast cancer risk among post-menopausal women not taking HT.  However, a trend for 
increased risk of breast cancer (OR 1.41-1.64, high tertile density vs low tertile density) when 
adjusting for the estrogen metabolites, BMI, and age was noted.  This finding is consistent with 
previous reports noting the increased risk with increasing density(7, 8, 31).  This breast density-
breast cancer association remains significant even with adjustment for the estrogen metabolites 
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 suggesting that breast density and estrogen metabolites independently contribute to breast cancer 
risk.  Factors associated with breast density in premenopausal women may differ from factors 
associated with breast density in post-menopausal women. 
In premenopausal women (high density tertile vs. low density tertile), the OR ranged from 
3.07 (95%CI 1.38-7.30) to 5.63 (95% CI 1.94-16.36) adjusting for BMI, estrogen metabolites 
and reproductive factors (ever pregnant, parity).  Postmenopausal women not taking HT, had 
greater OR 1.63-1.91 inclusive of the adjustment for age, BMI, pregnancy history, parity, and 
estrogen metabolites in the mid vs. low tertile compared to the high vs. low tertile OR (0.85-
1.27).  Breast cancer risk associated with breast cancer in postmenopausal women on HT (OR 
0.88-1.64 in high tertile vs. low tertile), revealed an association, strengthened when adjusted for 
the estrogen metabolites, BMI, and age. 
In contrast to the association between risk of breast cancer and breast density reported 
among both pre- and post menopausal women(7, 8, 31), we found that among post-menopausal 
women breast density appeared to protect against breast cancer, while not statistically significant.  
This association was evident in the evaluation of breast density alone and when adjusting for the 
estrogen metabolites and BMI.  The fact that in our population, breast density in postmenopausal 
women was not associated with breast cancer risk may be a result of the sample size or the 
inability in this dataset to determine if years since menopause is confounding the association.   
There are several features of the present study – used for article 2 and 3 - that warrant discussion.  
To our knowledge, this is the first study to examine breast density, serum estrogen metabolites, 
and breast cancer risk factors.  The use of a single, expert breast density reader helps to reduce 
variability in breast density measurements and subsequent measures of effect.  However, 
mammographic films were only available at one time point which limits the ability to identify 
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 changes in breast density over time with respect to age, menopausal status, as well as changes 
related to HT use.  The use of serum to measure estrogen metabolites in particular with 
premenopausal women may be subject to fluctuations in the menstrual cycle and therefore may 
not accurately reflect the level of estrogen metabolism.  In this study we utilized serum for the 
measurement of estrogen metabolites while most other studies have utilized urine.  In a study by 
Bradlow et al(9), plasma and urinary levels of 2OH and 16α-OH were compared in nulliparous 
women aged 17-35.  They concluded that the correlation varied across ethnic groups and 
baseline use of oral contraceptives and coffee consumption.  Additionally, the time at which the 
samples were collected during the menstrual cycle had an impact on the levels.  Overall, the 
correlation between the two methods was felt to be fair.  While the comparison was only 
conducted in premenopausal women it is suspected that the amount of variation would be less in 
the postmenopausal population.   
Lastly, reproductive and lifestyle factors were obtained by self-report which may lend to 
recall bias, thereby attenuating our results.  Additionally, we cannot exclude the possibility that 
our findings may be due to chance or confounded by some unidentified factor.   
 
5.7. Future Research 
In the first study, we evaluated the determinants of estrogen metabolism in postmenopausal 
women.  While this provided an opportunity to begin to understand the relationship between 
estrogen metabolism in the postmenopausal setting, the premenopausal setting deserves 
evaluation.  Measurement of metabolism levels in the premenopausal setting will need to account 
for menstrual cycle variations and the subsequent fluctuations in the estrogen metabolism levels.  
Lastly, the most effective medium for measurement of the estrogen metabolites remains to be 
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 determined.  Currently, urine and serum assays are available and both carry limitations.  
Identification of tools to enhance measurement of the metabolite levels, particularly at the tissue 
level would be optimal.  Lastly, the impact of HT and newer agents, in particular selective 
estrogen response modulators (SERMs) on estrogen metabolism and breast density warrants 
further investigation.   
Evidence suggests hormonal factors may be more strongly associated with estrogen 
receptor (ER)+/progesterone receptor (PR)+ than ER-/PR- breast cancer risk.  The presence of 
estrogen receptors in the primary tumor not only indicate likely response to hormonal therapy, 
but also confer a better prognosis(1, 17).  The role of estrogen metabolism and ER/PR status has 
not been evaluated and may potentially lend to the understanding of the relationship between 
those risk factors including breast density, which appears to be hormonally responsive.  As ER 
positive tumors confer a better prognostic factor in breast cancer, it would be useful to 
understand those factors, which may mediate the hormone receptor status.   
With respect to density, while we have made great progress in the measurement of density, 
the incorporation of better methods to capture the volume of breast density is crucial to fully 
appreciate the underlying biology and subsequent association with breast cancer risk.   
Finally, our study included predominantly white women and did not allow us to examine if 
similar relationships exist in the non-white population.  Considering that black women have 
demonstrated biological differences with respect to estrogen receptor status, studies 
incorporating different ethnic groups would be important to identify differences in estrogen 
metabolism and breast density as to optimize breast cancer prevention strategies.  
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 6. PUBLIC HEALTH SIGNIFICANCE 
 
This compilation of studies focused first on identifying the determinants of estrogen metabolism 
and then subsequently the relationship between estrogen metabolites and breast density, first in 
the control population and then across cases and controls.  The results demonstrated that except 
for BMI, 16α-OH, and surgical menopause, we did not see associations between the estrogen 
metabolites and the traditional risk factors.  Control for substrate hormones eliminated the BMI 
association, but not the association with type of menopause.  While it appears that the substrate 
hormone levels appear to mediate the association between BMI and 16α-OH, the apparent lack 
of residual association between BMI (and other risk factors) with 16α-OH or 2-OH suggests that 
inter-individual differences in hormone metabolism, per se, are insensitive to external factors.  
Further evaluation of the association between estrogen metabolites and breast density in  
controls, inclusive of pre-menopausal, post-menopausal women not taking hormone therapy 
(HT), and post-menopausal women taking HT, revealed that high serum concentrations of the 
16α-OH and 2-OH correlated with breast density. The associations between the estrogen 
metabolites and breast density appeared independent of post-menopausal hormone medication 
use. However, statistical associations disappeared upon control for menopausal status. This 
pattern of association is consistent with two possibilities. First, serum estrogen metabolite 
concentrations and breast density may share common determinants that are related to the 
menopause. Or, secondly, that estrogen metabolite changes, occurring as a consequence of 
menopause, may directly contribute to the menopause-associated declines in breast density. 
Determination of the menopause-specific cross-sectional associations between the serum 
estrogen metabolites and breast density may require larger studies, with sufficient numbers of 
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 pre- and post-menopausal women.  In the final paper, a breast density-breast cancer risk 
relationship, that is independent of serum estrogen metabolite concentrations, exists in subgroups 
of women classified according to menopausal status and HT use.  Factors associated with breast 
density in premenopausal women may differ from factors associated with breast density in post-
menopausal women. 
Breast density, outside of age and BRCA1 and BRCA2 mutations, is the strongest risk 
factor for breast cancer.  It is well known that screening mammography is the best way to reduce 
morbidity and mortality from breast cancer.  It is also well established that breast density affects 
the sensitivity and specificity of mammography and therefore can reduce the benefits of 
screening.  It has been postulated that if density were taken into account in the standard breast 
cancer risk assessment, up to 20% of postmenopausal women would be eligible for 
chemoprevention(1).  Therefore, understanding factors that affect breast density and their 
underlying mechanism is an important public health issue.  Such an understanding will help us 
improve breast cancer screening and may help us identify women who are at an increased risk of 
breast cancer and for whom prevention strategies may be useful.      
 
 
 
 
144 
 6.1. References 
 
1.   Boyd NF et al.  Mammographic breast density as an intermediate phenotype for breast 
cer. Lancet 6, 798-808. 2005.  can
 
145 
  
7. SUMMARY 
 
The study titled “Mammograms and Masses Study” (MAMS) was designed to evaluate the role 
of estrogen metabolism, hormone replacement therapy (HT), body mass index (BMI), and breast 
density in breast cancer.    The first article utilized a control population from the Study of 
Osteoporosis and Fractures (SOF) to answer the question regarding the determinants of estrogen 
metabolism.  Two hundred eight-two randomly selected women without breast cancer recruited 
from 1986-1988 using population-based lists in Baltimore, MD, Pittsburgh, PA, Minneapolis, 
MN, and Portland, OR were analyzed for this report.  Logistic regression was used to examine 
the independent association between the level of a particular estrogen metabolite and various 
factors including hormones (total estrogen and total testosterone concentration in blood), binding 
protein, and behavioral/reproductive breast cancer risk factors.  Analyses were conducted with a 
base model consisting of standardized log transformed estradiol, testosterone, and SHBG.  Age, 
BMI, and other statistically significant variables (p <0.10), identified in univariate analyses were 
added to the base model singly, to evaluate the metabolite levels in mid versus low tertile as well 
as high versus low tertile.     
Results did not show consistent associations between risk factors and estrogen metabolites 
except for a positive association between BMI and 16α-OH and surgical menopause and 16α-
OH.  When adjusting for the substrate hormones, the association between BMI and 16α-OH 
disappears suggesting that the hormones mediate the effect of BMI on 16α-OH.  However, the 
association between type of menopause and 16α-OH persists after adjustments for substrate 
hormone concentrations.  This tentative observation (higher 16α-OH in women, with surgical 
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 menopause, not explained by differences in substrate hormone concentrations) suggests surgical 
menopause may identify women who metabolize estrogen differently.  
The second article was designed to investigate the relationship between breast density and 
estrogen metabolism.  We measured breast density (area measure of visibly dense breast, 
expressed as a percentage of the total breast area on a standard two-dimensional mammogram) 
and serum concentrations of 2-OH and 16α-OH in 124 pre- and 256 post-menopausal women 
who lacked a diagnosis of breast cancer despite screening mammography or biopsy of suspicious 
breast abnormalities. To identify and recruit eligible subjects, a research assistant personally 
solicited women visiting the Breast Biopsy Service between September 2001 and May 2004 and 
women visiting Magee-Womancare Center – North (Wexford, Pennsylvania) and East 
(Monroeville, Pennsylvania) between July 2002 and September 2003.  To boost subject 
recruitment, Magee-Womens Hospital attached study flyers to screening result reports mailed to 
Magee-Womancare Center patrons with negative mammography between November 2003 and 
May 2004.  The study group included 124 pre-menopausal women (median age 46 years, range 
39-55 years; 115 white, 6 other, and 3 unknown race; 34% overweight (BMI 25.0-29.9 kg/m2) 
and 24% obese (BMI 30.0+ kg/m2); 4 N1, 19 P1, 96 P2, and 5 DY Wolfe parenchymal pattern; 
median breast density 41%, inter-quartile range (IQR) 26-56%) and 256 post-menopausal 
women (median age 59 years, range 44-84 years; 241 white, 11 other, and 4 unknown race; 37% 
overweight and 31% obese; 15 N1, 66 P1, 173 P2, and 2 DY Wolfe parenchymal pattern; median 
breast density 32%, IQR 16-49%). Forty-six (18%) and 210 (82%) post-menopausal women had 
experienced surgical and natural menopause, respectively. Among 251 post-menopausal women 
with known history of estrogen or progesterone hormone therapy (HT), 92 (37%) reported 
current use. 
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 In every subgroup defined according to menopausal status and current use of hormone 
therapy, analyses did not show statistically significant association between any single serum 
estrogen metabolite measure and age.  However, as previously noted by other investigators, an 
increase in BMI is associated, specifically in post-menopausal women taking hormone therapy, 
with a substantial decrease in 2-OH, 16α-OH and the 2:16α-OH ratio.  Using multiple linear 
regression, the effects of serum 2-OH and 16α-OH on breast density were evaluated.  
Unadjusted, both 2-OH and 16α-OH were associated with breast density, in pre-menopausal and 
post-menopausal women, HT-users and HT-nonusers, considered together.  This association 
remained even after adjustment for age and BMI.  Removing HT users, there was little change in 
the association noted in the entire subject population indicating that the effects of estrogen 
metabolism on breast density are independent of HT use.  However, once adjusted for 
menopausal status, while there is a trend for higher β 16α-OH values, no statistically significant 
association is noted in any of the subgroups. 
As in the first paper, it would have been helpful to evaluate the sex-steroid hormones and 
the estrogen metabolites.  However, menopausal status may serve as a proxy since the sex-
steroid hormone levels are related to menopausal status. 
In conclusion, there may be common determinants for both breast density and the estrogen 
metabolites or it is possible that menopausal status influences estrogen metabolite levels, which 
in turn influence breast density.   
Lastly, in the third article we sought to determine whether breast density and estrogen 
metabolites are independently associated with breast cancer risk.  The study sample included 380 
controls consisting of 192 (50.5%), 71 (18.7%), and 117 (30.8%) and 176 cases consisting of 80 
(45.4%), 94 (53.4%) 1 (0.6%), and 1 (0.6%), and women from the Magee-Womens Breast 
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 Biopsy Service , Surgical Clinic, Magee-Womancare Center – North/East, and mass mailings, 
respectively.  
Using logistic regression, the risk of breast cancer was evaluated across tertiles of density, 
both unadjusted and adjusted for age and BMI.  As expected, the risk of breast cancer in the high 
tertile vs. low tertile breast density was 3-4-fold even after adjusting for age and BMI in pre-
menopausal women.  With respect to primary hypotheses pertaining to the independence of 
association, adjustments for blood estrogen metabolite concentrations did not have any 
meaningful effect on the observed association between breast density and breast cancer risk in 
pre-menopausal women. 
Except perhaps for some elevation in breast cancer risk in post-menopausal women not 
taking HT with mid tertile relative to low tertile breast density, logistic regression analyses 
produced scant evidence for association between breast density and breast cancer risk in post-
menopausal women, unadjusted or adjusted for estrogen metabolite concentrations. Small sample 
sizes and wide confidence intervals limited ability to make meaningful inferences. Other factors 
possibly responsible for inability to demonstrate association between density and risk in post-
menopausal women include unrecognized selection bias related to recruitment of case and 
control subjects from diverse sources.  Through observer blinding, breast density was measured 
in a way independent of case-controls status. Therefore, systematic bias related to breast density 
determination is not likely. 
In conclusion, the breast density-breast cancer association remains significant even with 
adjustment for the estrogen metabolites, at least in pre-menopausal women, suggesting that 
breast density may relate to breast cancer risk through pathways not involving estrogen 
metabolism. 
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